US20190195879A1 - Methods for predicting therapeutic benefit of anti-cd19 therapy in patients - Google Patents
Methods for predicting therapeutic benefit of anti-cd19 therapy in patients Download PDFInfo
- Publication number
- US20190195879A1 US20190195879A1 US16/305,482 US201716305482A US2019195879A1 US 20190195879 A1 US20190195879 A1 US 20190195879A1 US 201716305482 A US201716305482 A US 201716305482A US 2019195879 A1 US2019195879 A1 US 2019195879A1
- Authority
- US
- United States
- Prior art keywords
- cells
- peripheral
- baseline
- antibody
- lymphoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 56
- 230000008901 benefit Effects 0.000 title claims abstract description 10
- 238000002560 therapeutic procedure Methods 0.000 title description 22
- 230000001225 therapeutic effect Effects 0.000 title description 5
- 210000000822 natural killer cell Anatomy 0.000 claims abstract description 190
- 230000002093 peripheral effect Effects 0.000 claims abstract description 140
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims abstract description 110
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims abstract description 91
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims abstract description 87
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims abstract description 87
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims abstract description 87
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims abstract description 87
- 239000000090 biomarker Substances 0.000 claims abstract description 55
- 238000011282 treatment Methods 0.000 claims abstract description 55
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims abstract description 34
- 210000004369 blood Anatomy 0.000 claims abstract description 17
- 239000008280 blood Substances 0.000 claims abstract description 17
- 210000004027 cell Anatomy 0.000 claims description 162
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 15
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 201000003444 follicular lymphoma Diseases 0.000 claims description 6
- 210000003563 lymphoid tissue Anatomy 0.000 claims description 5
- 210000004877 mucosa Anatomy 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 39
- 201000010099 disease Diseases 0.000 description 38
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 37
- 230000004044 response Effects 0.000 description 36
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 32
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 30
- 229960004641 rituximab Drugs 0.000 description 23
- 239000000523 sample Substances 0.000 description 23
- 210000001744 T-lymphocyte Anatomy 0.000 description 22
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 19
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 19
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 17
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 16
- 239000011324 bead Substances 0.000 description 15
- 238000002600 positron emission tomography Methods 0.000 description 15
- 230000004083 survival effect Effects 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 12
- 230000035945 sensitivity Effects 0.000 description 12
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical class O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 11
- 206010025323 Lymphomas Diseases 0.000 description 11
- 210000004698 lymphocyte Anatomy 0.000 description 11
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 description 11
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 10
- 230000002596 correlated effect Effects 0.000 description 10
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 10
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 10
- IFSDAJWBUCMOAH-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 IFSDAJWBUCMOAH-HNNXBMFYSA-N 0.000 description 10
- 208000032839 leukemia Diseases 0.000 description 10
- 229960001183 venetoclax Drugs 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 9
- 238000002591 computed tomography Methods 0.000 description 9
- 229960003445 idelalisib Drugs 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 150000003212 purines Chemical class 0.000 description 9
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 8
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 8
- 229960001507 ibrutinib Drugs 0.000 description 8
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 7
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 7
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 7
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 7
- 229960002707 bendamustine Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229960000390 fludarabine Drugs 0.000 description 7
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 108700028369 Alleles Proteins 0.000 description 6
- 208000003950 B-cell lymphoma Diseases 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 6
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 description 5
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 description 5
- 239000012664 BCL-2-inhibitor Substances 0.000 description 5
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 229960004397 cyclophosphamide Drugs 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000001647 drug administration Methods 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 229960004942 lenalidomide Drugs 0.000 description 5
- 229960003433 thalidomide Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108091007960 PI3Ks Proteins 0.000 description 4
- 102000038030 PI3Ks Human genes 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 201000009277 hairy cell leukemia Diseases 0.000 description 4
- 230000002934 lysing effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 229960004618 prednisone Drugs 0.000 description 4
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- ZSZXYWFCIKKZBT-IVYVYLGESA-N 1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5-trisphosphate) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)O[C@@H]1[C@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O ZSZXYWFCIKKZBT-IVYVYLGESA-N 0.000 description 3
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 description 3
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 description 3
- 229940125814 BTK kinase inhibitor Drugs 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- -1 CVID3 Proteins 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 238000009175 antibody therapy Methods 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 229960005304 fludarabine phosphate Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 208000021937 marginal zone lymphoma Diseases 0.000 description 3
- 229960004961 mechlorethamine Drugs 0.000 description 3
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 229960004528 vincristine Drugs 0.000 description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- XKJMBINCVNINCA-UHFFFAOYSA-N Alfalone Chemical compound CON(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XKJMBINCVNINCA-UHFFFAOYSA-N 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 108091008875 B cell receptors Proteins 0.000 description 2
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 101710117995 B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 108091007958 Class I PI3Ks Proteins 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 208000033766 Prolymphocytic Leukemia Diseases 0.000 description 2
- MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000009096 combination chemotherapy Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 210000005220 cytoplasmic tail Anatomy 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 150000001982 diacylglycerols Chemical class 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000002962 histologic effect Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000002625 monoclonal antibody therapy Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 208000037821 progressive disease Diseases 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000011476 stem cell transplantation Methods 0.000 description 2
- 238000009121 systemic therapy Methods 0.000 description 2
- 229940121503 tafasitamab Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 2
- FZIOMKFLUUMMRC-VKHMYHEASA-N (2s)-2-amino-3-oxo-3-(2-sulfinoethylamino)propanoic acid Chemical compound OC(=O)[C@@H](N)C(=O)NCCS(O)=O FZIOMKFLUUMMRC-VKHMYHEASA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 238000010176 18-FDG-positron emission tomography Methods 0.000 description 1
- LPLLVINFLBSFRP-UHFFFAOYSA-N 2-methylamino-1-phenylpropan-1-one Chemical compound CNC(C)C(=O)C1=CC=CC=C1 LPLLVINFLBSFRP-UHFFFAOYSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- SJVQHLPISAIATJ-ZDUSSCGKSA-N 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]-1-isoquinolinone Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 SJVQHLPISAIATJ-ZDUSSCGKSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 101100214873 Autographa californica nuclear polyhedrosis virus AC78 gene Proteins 0.000 description 1
- 208000037914 B-cell disorder Diseases 0.000 description 1
- 208000012526 B-cell neoplasm Diseases 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- KHFOUEDLYNCPEH-UHFFFAOYSA-N CC1(C)CCC(CN2CCN(C3=CC(OC4=NC5=C(C=CN5)C=C4)=C(C(=O)CS(=O)(=O)C4=CC=C(CCC5CCOCC5)C([N+](=O)[O-])=C4)C=C3)CC2)=C(C2=CC=C(Cl)C=C2)C1 Chemical compound CC1(C)CCC(CN2CCN(C3=CC(OC4=NC5=C(C=CN5)C=C4)=C(C(=O)CS(=O)(=O)C4=CC=C(CCC5CCOCC5)C([N+](=O)[O-])=C4)C=C3)CC2)=C(C2=CC=C(Cl)C=C2)C1 KHFOUEDLYNCPEH-UHFFFAOYSA-N 0.000 description 1
- IROVKHMTWFNLGI-KRWDZBQOSA-N CC[C@H](NC1=C2CC=NC2=NC=N1)C1=NC2=C(C(=O)N1C1=CC=CC=C1)C(F)=CC=C2 Chemical compound CC[C@H](NC1=C2CC=NC2=NC=N1)C1=NC2=C(C(=O)N1C1=CC=CC=C1)C(F)=CC=C2 IROVKHMTWFNLGI-KRWDZBQOSA-N 0.000 description 1
- 229940124292 CD20 monoclonal antibody Drugs 0.000 description 1
- 102100027221 CD81 antigen Human genes 0.000 description 1
- 201000004085 CLL/SLL Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102100032768 Complement receptor type 2 Human genes 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 240000003023 Cosmos bipinnatus Species 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229940126161 DNA alkylating agent Drugs 0.000 description 1
- 239000012624 DNA alkylating agent Substances 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229940126656 GS-4224 Drugs 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 description 1
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 208000011821 Indolent B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 206010025280 Lymphocytosis Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- GIUYCYHIANZCFB-ACJOCUEISA-N NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](COP(=O)(O)O)[C@H](O)C1O Chemical compound NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](COP(=O)(O)O)[C@H](O)C1O GIUYCYHIANZCFB-ACJOCUEISA-N 0.000 description 1
- 101150037263 PIP2 gene Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 102000038012 SFKs Human genes 0.000 description 1
- 108091008118 SFKs Proteins 0.000 description 1
- 101100262439 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UBA2 gene Proteins 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 208000025317 T-cell and NK-cell neoplasm Diseases 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 1
- 101710086214 Tyrosine-protein kinase BTK Proteins 0.000 description 1
- 229940127174 UCHT1 Drugs 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 208000018805 childhood acute lymphoblastic leukemia Diseases 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 208000023738 chronic lymphocytic leukemia/small lymphocytic lymphoma Diseases 0.000 description 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 229950002550 copanlisib Drugs 0.000 description 1
- PZBCKZWLPGJMAO-UHFFFAOYSA-N copanlisib Chemical compound C1=CC=2C3=NCCN3C(NC(=O)C=3C=NC(N)=NC=3)=NC=2C(OC)=C1OCCCN1CCOCC1 PZBCKZWLPGJMAO-UHFFFAOYSA-N 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229950004949 duvelisib Drugs 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 210000000285 follicular dendritic cell Anatomy 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000011396 initial chemotherapy Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 201000000638 mature B-cell neoplasm Diseases 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Chemical class 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 208000010915 neoplasm of mature B-cells Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229960000688 pomalidomide Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 238000011363 radioimmunotherapy Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 238000009804 total hysterectomy Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229940066958 treanda Drugs 0.000 description 1
- 238000009810 tubal ligation Methods 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 229960002110 vincristine sulfate Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229940095188 zydelig Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- the present disclosure is directed to identifying characteristics and biomarkers in patients that benefit from treatment with anti-CD19 antibodies.
- CD19 is a 95-kDa transmembrane glycoprotein of the immunoglobulin superfamily containing two extracellular immunoglobulin-like domains and an extensive cytoplasmic tail.
- the protein is a pan-B lymphocyte surface receptor and is ubiquitously expressed from the earliest stages of pre-B cell development onwards until it is down-regulated during terminal differentiation into plasma cells. It is B-lymphocyte lineage specific and not expressed on hematopoietic stem cells and other immune cells, except some follicular dendritic cells.
- CD19 functions as a positive regulator of B cell receptor (BCR) signaling and is important for B cell activation and proliferation and in the development of humoral immune responses.
- BCR B cell receptor
- CD19 acts as a co-stimulatory molecule in conjunction with CD21 and CD81 and is critical for B cell responses to T-cell-dependent antigens.
- the cytoplasmic tail of CD19 is physically associated with a family of tyrosine kinases that trigger downstream signaling pathways via the src-family of protein tyrosine kinases.
- CD19 is an attractive target for cancers of lymphoid origin since it is highly expressed in nearly all chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphomas (NHL), as well as many other different types of leukemias, including acute lymphocytic leukemia (ALL) and hairy cell leukemia (HCL).
- CLL chronic lymphocytic leukemia
- NHL non-Hodgkin's lymphomas
- ALL acute lymphocytic leukemia
- HCL hairy cell leukemia
- MOR00208 (previously named XmAb5574) is an Fc engineered humanized monoclonal antibody that binds CD19.
- ADCC antibody dependent cell-mediated cytotoxicity
- ADCP antibody dependent cell-mediated phagocytosis
- apoptosis direct cytotoxic effects
- MOR00208 has or is currently being studied in clinical trials in CLL, ALL and NHL. Specifically, a Phase I trial titled Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia, and a Phase Ila trial titled Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to treat B-cell Acute Lymphoblastic Leukemia (B-ALL) are completed. A Phase Ila trial titled Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL) has completed recruitment.
- B-ALL B-cell Acute Lymphoblastic Leukemia
- NK natural killer
- MOR00208 has been studied in patients having CLL, ALL, NHL and SLL. Accordingly, a thorough analysis of clinical data has been completed to date in order to identify characteristics or biomarkers of patients that are more likely to benefit from MOR00208 treatment.
- MOR00208 specifically targets the CD19 surface antigen and mediates direct tumor cell killing via its enhanced ADCC effector function.
- MOR00208 has been shown to significantly enhance in vitro ADCC, ADCP, and direct cytotoxic effects (apoptosis) on CD19 + tumor cell lines spanning a broad range of human lymphomas and leukemias (Burkitt's lymphoma, CLL, hairy cell leukemia (HCL), CD19+ chronic myeloid leukemia (CML), diffuse large B cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL), expressing levels of CD19 antigen ranging from 15,000 to 105,000 molecules/cell.
- Burkitt's lymphoma, CLL hairy cell leukemia
- CML CD19+ chronic myeloid leukemia
- DLBCL diffuse large B cell lymphoma
- ALL acute lymphoblastic leukemia
- DCR Disease Control Rate
- DCR includes patients have Complete Response (CR)+Partial Response (PR)+Stable Disease (SD). Additionally, such patients had a significantly better Progression Free Survival (PFS) as compared to patients having lower NK cells counts.
- PFS Progression Free Survival
- ABS Disease Control Rate
- DCR Disease Control Rate
- DCR includes patients have Complete Response (CR)+Partial Response (PR)+Stable Disease (SD).
- PFS Progression Free Survival
- ABS Progression Free Survival
- DCR Disease Control Rate
- DCR includes patients have Complete Response (CR)+Partial Response (PR)+Stable Disease (SD).
- PFS Progression Free Survival
- ABS Progression Free Survival
- FIG. 1 shows the amino acid sequences of MOR00208 variable domains and CDRs.
- FIG. 2 shows the amino acid sequences of MOR00208′s full heavy and light chains.
- FIG. 3 shows the Receive Operating Characteristic (ROC) analysis of peripheral NK cell counts as a predictor for DCR.
- FIG. 4 shows the ROC analysis of CD16 expression levels on peripheral NK cells (ABCs) as a predictor for DCR.
- FIG. 5 shows the ROC analysis of peripheral T cell count as a potential predictor for DCR.
- FIG. 6 shows that peripheral NK cell counts and CD16 expression levels on peripheral NK cells are independent variables and not correlated.
- FIG. 7 shows the Forest Plot with DCRs in patient subgroups with specific baseline characteristics and biomarkers
- FIG. 8 shows the progression free survival difference between patients having at least 100 cells/ ⁇ l peripheral NK cell counts versus patients having lower NK cell counts.
- FIG. 9 shows the progression free survival difference between patients having at least 60,000 ABCs in CD16 expression on peripheral NK cells versus patients having lower CD16 expression on NK cells.
- FIG. 10 shows the progression free survival difference between patients having at least 500 cells/ ⁇ l peripheral T cell counts versus patients having lower T cell counts.
- antibody means monoclonal antibodies, including any isotype, such as, IgG, IgM, IgA, IgD and IgE.
- An IgG antibody is comprised of two identical heavy chains and two identical light chains that are joined by disulfide bonds. Each heavy and light chain contains a constant region and a variable region. Each variable region contains three segments called “complementarity-determining regions” (“CDRs”) or “hypervariable regions”, which are primarily responsible for binding an epitope of an antigen. They are referred to as CDR1, CDR2, and CDR3, numbered sequentially from the N-terminus. The more highly conserved portions of the variable regions outside of the CDRs are called the “framework regions”.
- an “antibody fragment” means an Fv, scFv, dsFv, Fab, Fab′ F(ab′)2 fragment, or other fragment, which contains at least one variable heavy or variable light chain, each containing CDRs and framework regions.
- VH refers to the variable region of an immunoglobulin heavy chain of an antibody, or antibody fragment.
- VL refers to the variable region of the immunoglobulin light chain of an antibody, or antibody fragment.
- Fc region means the constant region of an antibody, which in humans may be of the IgG1, 2, 3, 4 subclass or others.
- the sequences of human Fc regions are available at IMGT, Human IGH C-REGIONs, www.imgt.org/IMGTrepertoire/Proteins/protein/human/IGH/IGHC/Hu_IGHCallgenes.html (retrieved on 16 May 2011).
- patient includes a human.
- NHL is a heterogeneous malignancy originating from lymphocytes.
- U.S. United States
- the incidence is estimated at 65,000/year with mortality of approximately 20,000 (American Cancer Society, 2006; and SEER Cancer Statistics Review).
- the disease can occur in all ages, the usual onset begins in adults over 40 years, with the incidence increasing with age.
- NHL is characterized by a clonal proliferation of lymphocytes that accumulate in the lymph nodes, blood, bone marrow and spleen, although any major organ may be involved.
- the current classification system used by pathologists and clinicians is the World Health Organization (WHO) Classification of Tumours, which organizes NHL into precursor and mature B-cell or T-cell neoplasms.
- WHO World Health Organization
- the PDQ is currently dividing NHL as indolent or aggressive for entry into clinical trials.
- the indolent NHL group is comprised primarily of follicular subtypes, small lymphocytic lymphoma, MALT (mucosa-associated lymphoid tissue), and marginal zone; indolent encompasses approximately 50% of newly diagnosed B-cell NHL patients.
- Aggressive NHL includes patients with histologic diagnoses of primarily diffuse large B cell (DLBL, DLBCL, or DLCL) (40% of all newly diagnosed patients have diffuse large cell), Burkitt's, and mantle cell.
- the clinical course of NHL is highly variable. A major determinant of clinical course is the histologic subtype. Most indolent types of NHL are considered to be incurable disease.
- rituximab anti-CD20 antibody
- R-CHOP rituximab+CHOP
- R-CVP rituximab+CVP
- Rituximab therapy has been shown to be efficacious in several types of NHL, and is currently approved as a first line treatment for both indolent (follicular lymphoma) and aggressive NHL (diffuse large B cell lymphoma).
- indolent follicular lymphoma
- aggressive NHL diffuse large B cell lymphoma
- anti-CD20 monoclonal antibody mAb
- primary resistance 50% response in relapsed indolent patients
- acquired resistance 50% response rate upon re-treatment
- rare complete response 2% complete resonse rate in relapsed population
- a continued pattern of relapse a continued pattern of relapse.
- B cells do not express CD20, and thus many B-cell disorders are not treatable using anti-CD20 antibody therapy.
- Chronic lymphocytic leukemia also known as “chronic lymphoid leukemia” or “CLL”
- CLL chronic lymphocytic leukemia
- the malignant lymphocytes may look normal and mature, but they are not able to cope effectively with infection.
- CLL is the most common form of leukemia in adults. Men are twice as likely to develop CLL as women.
- the key risk factor is age. Over 75% of new cases are diagnosed in patients over age 50. More than 10,000 cases are diagnosed every year and the mortality is almost 5,000 a year (American Cancer Society, 2006; and SEER Cancer Statistics Review).
- CLL is an incurable disease but progresses slowly in most cases. Many people with CLL lead normal and active lives for many years. Because of its slow onset, early-stage CLL is generally not treated since it is believed that early CLL intervention does not improve survival time or quality of life. Instead, the condition is monitored over time.
- Initial CLL treatments vary depending on the exact diagnosis and the progression of the disease. There are dozens of agents used for CLL therapy. Combination chemotherapy regimens such as FCR (fludarabine, cyclophosphamide and rituximab), and BR (Ibrutinib and rituximab) are effective in both newly-diagnosed and relapsed CLL. Allogeneic bone marrow (stem cell) transplantation is rarely used as a first-line treatment for CLL due to its risk.
- SLL Small lymphocytic lymphoma
- CLL Small lymphocytic lymphoma
- the definition of SLL requires the presence of lymphadenopathy and/or splenomegaly.
- the number of B lymphocytes in the peripheral blood should not exceed 5 ⁇ 109/L.
- the diagnosis should be confirmed by histopathologic evaluation of a lymph node biopsy whenever possible (Hallek et al., 2008).
- the incidence of SLL is approximately 25% of CLL in the US (Dores et al., 2007).
- ALL acute lymphoblastic leukemia
- ALL is characterized by the overproduction and continuous multiplication of malignant and immature white blood cells (also known as lymphoblasts) in the bone marrow.
- Acute refers to the undifferentiated, immature state of the circulating lymphocytes (“blasts”), and that the disease progresses rapidly with life expectancy of weeks to months if left untreated.
- ALL is most common in childhood with a peak incidence of 4-5 years of age. Children of age 12-16 die more easily from it than others. Currently, at least 80% of childhood ALL are considered curable. Under 4,000 cases are diagnosed every year and the mortality is almost 1,500 a year (American Cancer Society, 2006; and SEER Cancer Statistics Review).
- CD19 antibody in non-specific B cell lymphomas is discussed in WO2007076950 (US2007154473), which are both incorporated by reference.
- CD19 antibody in CLL, NHL and ALL is described in Scheuermann et al., CD19 Antigen in Leukemia and Lymphoma Diagnosis and Immunotherapy, Leukemia and Lymphoma, Vol. 18, 385-397 (1995), which is incorporated by reference in its entirety.
- CD19 refers to the protein known as CD19, having the following synonyms: B4, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, CVID3, Differentiation antigen CD19, MGC12802, and T-cell surface antigen Leu-12.
- Human CD19 has the amino acid sequence of:
- MOR00208 is an anti-CD19 antibody.
- the amino acid sequence of the variable domains is provided in FIG. 1 .
- the amino acid sequence of the heavy and light chain Fc regions of MOR00208 are provided in FIG. 2 .
- “MOR00208” and “XmAb 5574” are used as synonyms to describe the antibody shown in FIGS. 1 and 2 .
- the MOR00208 antibody is described in U.S. patent application Ser. No. 12/377,251, which is incorporated by reference in its entirety.
- a pharmaceutical composition includes an active agent, e.g. an antibody for therapeutic use in humans.
- a pharmaceutical composition may additionally include pharmaceutically acceptable carriers or excipients.
- administering refers to the delivery of a pharmaceutical composition by an injectable form, such as, for example, an intravenous, intramuscular, intradermal or subcutaneous route or mucosal route, for example, as a nasal spray or aerosol for inhalation or as an ingestable solution, capsule or tablet.
- injectable form such as, for example, an intravenous, intramuscular, intradermal or subcutaneous route or mucosal route, for example, as a nasal spray or aerosol for inhalation or as an ingestable solution, capsule or tablet.
- the antibody which is administered according to the present disclosure is administered to the patient in a therapeutically effective amount.
- a “therapeutically effective amount” refers to an amount sufficient to provide some improvement of the clinical manifestations of a given disease or disorder.
- patients in the exemplified study received dosing of MOR00208 at 12 mg/kg once weekly, and in maintenance once every two weeks or monthly.
- the amount that is effective for a particular therapeutic purpose will depend on the severity of the disease or injury as well as on the weight and general state of the subject. It will be understood that determination of an appropriate dosage may be achieved, using routine experimentation, by constructing a matrix of values and testing different points in the matrix, all of which is within the ordinary skills of a trained physician or clinical scientist.
- Baseline means prior to administration of the desired therapy. For example, prior to administration of the desired anti-CD19 antibody.
- ROC receiver operating characteristic
- Optimal Cutpoints An R Package for Selecting Optimal Cutpoints in Diagnostic Tests. Journal of Statistical Software 61(8), 1-36.
- Antibodies specific to CD19 have also been tested preclinically in combination with other drugs.
- MOR00208 had been tested in combination with nitrogen mustards, purine analogs, thalidomide analogs, phosphoinositide 3-kinase inhibitor, BCL-2 inhibitors and bruton's tyrosine kinase (BTK) inhibitors.
- a “nitrogen mustard” is a nonspecific DNA alkylating agent used as chemotherapy.
- Alkylating agents add an alkyl group (CnH2n+1) to nucleic acid bases, e.g., adding an alkyl group to the guanine base of DNA at the number 7 nitrogen atom of the imidazole ring.
- the alkylation steps result in the formation of interstrand cross-links (ICLs).
- ICLs interstrand cross-links
- Nitrogen mustards include cyclophosphamide, chlorambucil, uramustine, ifosfamide, melphalan and bendamustine.
- Bendamustine is marketed under the names Ribomustin®,and Treanda®, and is also known as SDX-105, by Mundipharma International Corporation Limited (Licensee of Astellas Pharma GmbH) and Cephalon for the treatment of chronic lymphocytic leukemias (CLL), indolent B-cell non-Hodgkin's lymphoma (NHL), and other lymphomas.
- Bendamustine has the following structure:
- a purine analog is an antimetabolite, which mimics the structure of metabolic purines, thereby interfering with the synthesis of nucleic acids.
- Fludarabine for example, may be incorporated into RNA and DNA by substituting for the purine nucleotides, adenine and guanine.
- Purine analogs inhibit growth of fast proliferating cells of an individual, e.g. cancer cells, bone marrow cells or cells present in the gastrointestinal tract.
- Purine analogs include mercaptopurine, azathioprine, thioguanine and fludarabine.
- Fludarabine or fludarabine phosphate is a chemotherapy drug used in the treatment of chronic lymphocytic leukemia and indolent non-Hodgkins lymphomas. Fludarabine is a purine analog. Fludarabine inhibits DNA synthesis by interfering with ribonucleotide reductase and DNA polymerase and is S phase-specific (since these enzymes are highly active during DNA replication). Fludarabine has the following structure:
- a “thalidomide analog” includes, but is not limited to, thalidomide itself, lenalidomide (CC-5013, RevlimidTM), Pomalidomide (CC4047, ActimidTM) and the compounds disclosed in WO2002068414 and WO2005016326, which are incorporated by reference in their entireties.
- the term refers to a synthetic chemical compound using the thalidomide structure as a backbone (e.g., side groups have been added or such groups have been deleted from the parent structure).
- the analog differs in structure from thalidomide and its metabolite compounds such as by a difference in the length of an alkyl chain, a molecular fragment, by one or more functional groups, or a change in ionization.
- thalidomide analog also includes the metabolites of thalidomide.
- Thalidomide analogs include the racemic mixture of the S- and the R-enantiomer of a respective compound and the S-enantiomer or to the R-enantiomer individually. The racemic mixture is preferred.
- Thalidomide analogs include the compounds of the following structures:
- a “phosphoinositide 3-kinase inhibitor” is a class of medical drug that functions by inhibiting one or more of the phosphoinositide 3-kinase enzymes, which are part of the PI3K/AKT/mTOR pathway, an important signalling pathway for many cellular functions such as growth control, metabolism and translation initiation.
- Class 1 PI3Ks have a catalytic subunit known as p110, with four types (isoforms)—p110 alpha, p110 beta, p110 gamma and p110 delta.
- Current inhibitors being studied inhibit one or more isoforms of the class I PI3Ks.
- Phosphoinositide 3-kinase inhibitors include at least Idelalisib, Duvelisib and Copanlisib.
- Idelalisib is marketed by Gilead Sciences, Inc. (trade name Zydelig, also named GS-1101 or CAL-101).
- Idelalisib is currently labelled for the treatment of relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities; relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies; relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies.
- the substance acts as a phosphoinositide 3-kinase inhibitor; more specifically, it blocks P110 ⁇ , the delta isoform of the enzyme phosphoinositide 3-kinase.
- BTK Bruton's tyrosine kinase inhibitor
- PIP3 phosphatidylinositol (3,4,5)-trisphosphate
- PIP3 binding induces Btk to phosphorylate phospholipase C, which in turn hydrolyzes PIP2, a phosphatidylinositol, into two second messengers, inositol triphosphate (IP3) and diacylglycerol (DAG), which then go on to modulate the activity of downstream proteins during B-cell signalling.
- IP3 inositol triphosphate
- DAG diacylglycerol
- Bruton's tyrosine kinase (BTK) inhibitors include Ibrutinib.
- Ibrutinib is marketed by Pharmacyclics, Inc and Johnson & Johnson's Janssen Pharmaceutical (trade name Imbruvica, also named PCI-32765).
- Ibrutinib is currently labelled for the treatment of patients with Mantle cell lymphoma (MCL) who have received at least one prior therapy, Chronic lymphocytic leukemia (CLL) who have received at least one prior therapy, Chronic lymphocytic leukemia with 17p deletion, and Waldenstrom's macroglobulinemia.
- MCL Mantle cell lymphoma
- CLL Chronic lymphocytic leukemia
- Chronic lymphocytic leukemia with 17p deletion and Waldenstrom's macroglobulinemia.
- Ibrutinib is 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one and has the following structure:
- a “BCL-2 inhibitor” is a class of drug that functions by inhibiting anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein, leading to programmed cell death of cells.
- BCL-2 inhibitor include venetoclax. Venetoclax is marketed by Abbvie and Genentech (trade name VENCLEXTATM, also known as GDC-0199, ABT-199, and RG7601). Venetoclax is currently labelled for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy.
- CLL chronic lymphocytic leukemia
- venetoclax is 4-(4- ⁇ [2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]nethyl ⁇ -1-piperazinyl)-N-( ⁇ 3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl ⁇ sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide and has the following structure:
- Venetoclax “ABT”, and “ABT-199” are used as synonyms herein.
- An aspect is a method of identifying a subject having chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) or small lymphocytic lymphoma (SLL) that is responsive to treatment with an anti-CD19 antibody, said method comprising:
- the sample is a blood sample.
- said sample comprises peripheral NK cells.
- the predetermined cut off level of said biomarker is a baseline peripheral NK cell count of at least 50 cells/ ⁇ l, at least 75 cells/ ⁇ l, at least 100 cells/ ⁇ l, at least 125 cells/ ⁇ l, at least 150 cells/ ⁇ l, at least 175 cells/ ⁇ l, at least 200 cells/ ⁇ l, at least 225 cells/ ⁇ l, or at least 250 cells/ ⁇ l.
- the predetermined cut off level of said biomarker is baseline CD16 expression levels on peripheral NK cells of at least 45,000 ABCs, at least 60,000 ABCs, at least 75,000 ABCs, or at least 90,000 ABCs.
- the predetermined cut off of said biomarker is:
- the predetermined cut of said biomarker is:
- predetermined cut off level a baseline peripheral NK cell count of at least 50 cells/ ⁇ l.
- the predetermined cut of said biomarker is baseline CD16 expression levels on peripheral NK cells of at least 60,000 (ABCs).
- the predetermined cut off of said biomarker is:
- the predetermined cut off of said biomarker is:
- predetermined cut off level a baseline peripheral NK cell count of at least 70 cells/ ⁇ l.
- the predetermined cut of said biomarker is baseline CD16 expression levels on peripheral NK cells of at least 60,000 (ABCs).
- the predetermined cut off of said biomarker is:
- the predetermined cut off of said biomarker is:
- predetermined cut off level a baseline peripheral NK cell count of at least 80 cells/ ⁇ l.
- the predetermined cut of said biomarker is baseline CD16 expression levels on peripheral NK cells of at least 60,000 (ABCs).
- the predetermined cut off of said biomarker is:
- the predetermined cut off of said biomarker is:
- predetermined cut off level a baseline peripheral NK cell count of at least 90 cells/ ⁇ l.
- the predetermined cut of said biomarker is baseline CD16 expression levels on peripheral NK cells of at least 60,000 (ABCs).
- the predetermined cut off of said biomarker is:
- the predetermined cut off of said biomarker is:
- predetermined cut off level a baseline peripheral NK cell count of at least 100 cells/ ⁇ l.
- the predetermined cut of said biomarker is baseline CD16 expression levels on peripheral NK cells of at least 60,000 (ABCs).
- An aspect is a method of identifying a subject having chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) or small lymphocytic lymphoma (SLL) that is responsive to treatment with an anti-CD19 antibody, said method comprising:
- An aspect is a method of identifying a subject having chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) or small lymphocytic lymphoma (SLL) that is responsive to treatment with an anti-CD19 antibody, said method comprising:
- the predetermined cut of said biomarker is:
- the predetermined cut off level of said biomarker is a baseline peripheral NK cell count of at least 50 cells/ ⁇ l, at least 75 cells/ ⁇ l, at least 100 cells/ ⁇ l, at least 125 cells/ ⁇ l, at least 150 cells/ ⁇ l, at least 175 cells/ ⁇ l, at least 200 cells/ ⁇ l, at least 225 cells/ ⁇ l, or at least 250 cells/ ⁇ l.
- the predetermined cut off level of said biomarker is baseline CD16 expression levels on peripheral NK cells of at least 45,000 ABCs, at least 60,000 ABCs, at least 75,000 ABCs, or at least 90,000 ABCs.
- An aspect is a method of treating a patient having chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) or small lymphocytic lymphoma (SLL) with an anti-CD19 antibody, the method comprising
- An aspect is a method of treating a patient having chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) or small lymphocytic lymphoma (SLL) with an anti-CD19 antibody, the method comprising
- the method of treating a patient chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) or small lymphocytic lymphoma (SLL) with an anti-CD19 antibody comprises
- the method of treating a patient chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) or small lymphocytic lymphoma (SLL) with an anti-CD19 antibody comprises
- the method of treating a patient chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) or small lymphocytic lymphoma (SLL) with an anti-CD19 antibody comprises
- the method of treating a patient having chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) or small lymphocytic lymphoma (SLL) with an anti-CD19 antibody comprises
- the anti-CD19 antibody is administered to patients having both a baseline peripheral NK cell count of of at least 50 cells/ ⁇ l, at least 60 cells/ ⁇ l, at least 70 cells/ ⁇ l, at least 80 cells/ ⁇ l, at least 90 cells/ ⁇ l or at least 100 cells/ ⁇ l, and a baseline CD16 expression level on peripheral NK cells of at least 60,000 (ABCs).
- ABSCs 60,000
- the anti-CD19 antibody is administered to patients having both a baseline peripheral NK cell count of at least 100 cells/ ⁇ l, and a baseline CD16 expression level on peripheral NK cells of at least 60,000 (ABCs).
- the anti-CD19 antibody is administered to patients having a baseline peripheral NK cell count of at least 50 cells/ ⁇ l, at least 75 cells/ ⁇ l, at least 100 cells/ ⁇ l, at least 125 cells/ ⁇ l, at least 150 cells/ ⁇ l, at least 175 cells/ ⁇ l, at least 200 cells/ ⁇ l, at least 225 cells/ ⁇ l, or at least 250 cells/ ⁇ l.
- the anti-CD19 antibody is administered to patients having baseline CD16 expression levels on peripheral NK cells of at least 45,000 ABCs, at least 60,000 ABCs, at least 75,000 ABCs, or at least 90,000 ABCs.
- An aspect is a method of treating a patient having chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) or small lymphocytic lymphoma (SLL) with an anti-CD19 antibody, said method comprising:
- An aspect is a method of treating a patient having chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) or small lymphocytic lymphoma (SLL) comprising administering an effective amount of an anti-CD19 antibody to the patient if
- CLL chronic lymphocytic leukemia
- NHL non-Hodgkin's lymphoma
- ALL acute lymphoblastic leukemia
- SLL small lymphocytic lymphoma
- An aspect is a method of treating a patient having chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) or small lymphocytic lymphoma (SLL) comprising
- An aspect is a method of treating a patient having chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) or small lymphocytic lymphoma (SLL) comprising
- anti-CD19 antibody is administered to patients having both a baseline peripheral NK cell count of at least 100 cells/ ⁇ l and a baseline CD16 expression level on peripheral NK cells of at least 60,000 (ABCs).
- the anti-CD19 antibody is administered to patients having a baseline peripheral NK cell count of at least 50 cells/ ⁇ l, at least 75 cells/ ⁇ l, at least 100 cells/ ⁇ l, at least 125 cells/ ⁇ l, at least 150 cells/ ⁇ l, at least 175 cells/ ⁇ l, at least 200 cells/ ⁇ l at least 225 cells/ ⁇ l, or at least 250 cells/ ⁇ l.
- the anti-CD19 antibody is administered to patients having baseline CD16 expression levels on peripheral NK cells of at least 45,000 ABCs, at least 60,000 ABCs, at least 75,000 ABCs, or at least 90,000 ABCs.
- the baseline peripheral NK cell count or baseline CD16 levels (ABCs) on the peripheral NK cells is obtained from a blood sample taken from the patient.
- the peripheral NK cell count and/or the CD16 expression levels are measured prior to administration of the anti-CD19 antibody.
- the antibody specific for CD19 comprises an HCDR1 region comprising the sequence SYVMH (SEQ ID NO: 1), an HCDR2 region comprising the sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region comprising the sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region comprising the sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region comprising the sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region comprising the sequence MQHLEYPIT (SEQ ID NO: 6).
- the baseline peripheral NK cell count or baseline CD16 expression levels on the peripheral NK cells is obtained from a blood sample taken from the patient.
- the patient has non-Hodgkin's lymphoma.
- the non-Hodgkin's lymphoma is selected from the group consisting of follicular lymphoma, small lymphocytic lymphoma, mucosa-associated lymphoid tissue, marginal zone, diffuse large B cell, Burkitt's, and mantle cell.
- the non-Hodgkin's lymphoma is follicular lymphoma.
- the non-Hodgkin's lymphoma is indolent non-Hodgkin's lymphoma.
- the non-Hodgkin's lymphoma is small lymphocytic lymphoma.
- the non-Hodgkin's lymphoma is mucosa-associated lymphoid tissue. In an embodiment, the non-Hodgkin's lymphoma is marginal zone lymphoma. In an embodiment, the non-Hodgkin's lymphoma is diffuse large B cell lymphoma. In an embodiment, the non-Hodgkin's lymphoma is Burkitt's lymphoma. In an embodiment, the non-Hodgkin's lymphoma is mantle cell lymphoma. In an embodiment, the patient has chronic lymphocytic leukemia. In an embodiment, the patient has acute lymphoblastic leukemia. In an embodiment, the patient has small lymphocytic lymphoma (SLL).
- SLL small lymphocytic lymphoma
- the treatment results in the therapeutic effect selected from the group consisting of Disease Control Rate (DCR) and longer duration of Progression Free Survival.
- DCR Disease Control Rate
- the treatment further comprises administration of an effective amount of a nitrogen mustard. In an embodiment that nitrogen mustard is bendamustine. In embodiments, the treatment further comprises administration of an effective amount of a purine analog. In embodiments, the purine analog is fludarabine. In embodiments, the treatment further comprises administration of an effective amount of a Bruton's tyrosine kinase (BTK) inhibitor. In embodiments, the Bruton's tyrosine kinase (BTK) inhibitor is ibrutinib. In embodiments, the treatment further comprises administration of an effective amount of a phosphoinositide 3-kinase inhibitor. In an embodiment the phosphoinositide 3-kinase inhibitor is idelalisib.
- the treatment further comprises administration of an effective amount of a thalidomide analog.
- the thalidomide analog is lenalidomide.
- the treatment further comprises administration of an effective amount of a BCL-2 inhibitor.
- the BCL-2 inhibitor is venetoclax.
- anti-CD19 antibody and other anti-CD19 antibodies bind CD19, it is believed that similar results may be seen with other anti-CD19 antibodies.
- Other anti-CD19 antibodies are described in U.S. patent application Ser. No. 12/377,251 (Xencor), WO2005012493, WO2010053716 (Immunomedics); WO2007002223 (Medarex); WO2008022152 (Xencor); WO2008031056 (Medimmune); WO 2007/076950 (Merck Patent GmbH); WO 2009/052431 (Seattle Genetics); and WO2010095031 (Glenmark Pharmaceuticals), all of which are incorporated by reference in their entireties.
- the antibody specific for CD19 comprises an antibody that cross-competes with the antibody comprising an HCDR1 region comprising the sequence SYVMH (SEQ ID NO: 1), an HCDR2 region comprising the sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region comprising the sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region comprising the sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region comprising the sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region comprising the sequence MQHLEYPIT (SEQ ID NO: 6).
- the antibody specific for CD19 comprises an antibody that binds to the same epitope as an antibody comprising an HCDR1 region comprising the sequence SYVMH (SEQ ID NO: 1), an HCDR2 region comprising the sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region comprising the sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region comprising the sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region comprising the sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region comprising the sequence MQHLEYPIT (SEQ ID NO: 6).
- the antibody specific for CD19 comprises an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6).
- the antibody specific for CD19 comprises a variable heavy chain of the sequence
- the antibody specific for CD19 comprises a light chain constant domain of the sequence RTVAAPSVFI FP PS DEQLKSGTASVVCLLN N FYPREAKVQWKVDNALQSG NSQESVTEQDS KD STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC. (SEQ ID NO: 13).
- the antibody specific for CD19 comprises a heavy chain having the sequence
- the antibody specific for CD19 comprises a light chain having the sequence
- Embodiments comprise a pharmaceutical composition.
- the composition comprises an acceptable carrier.
- the composition is administered in an effective amount.
- T cells are a type of lymphocyte (a subtype of white blood cell) that play a central role in cell-mediated immunity. They can be distinguished from other lymphocytes, such as B cells and NK cells, by the presence of a T-cell receptor on the cell surface.
- NK cells Natural killer cells or NK cells are a type of cytotoxic lymphocyte critical to the innate immune system. NK cells provide rapid responses to viral-infected cells, acting at around 3 days after infection, and respond to tumor formation. Typically, immune cells detect major histocompatibility complex (MHC) presented on infected cell surfaces, triggering cytokine release, causing lysis or apoptosis. NK cells are unique, however, as they have the ability to recognize stressed cells in the absence of antibodies and MHC, allowing for a much faster immune reaction.
- MHC major histocompatibility complex
- TriTest CD3 FITC/CD16+CD56 PE/CD45 PerCP (with TruCOUNT tubes), BD Biosciences, Cat: 340403 (US); 342442 (Europe). Pipettors and pipet tips capable of delivering 20 ⁇ L, 50 ⁇ L and 450 ⁇ L, Gilson Inc. FACS Lysing Solutions, BD Biosciences, Cat: 349202.
- TriTEST reagents Fluorescence triggering, allowing direct fluorescence gating of the NK- and T-cell lymphocyte population to reduce contamination of unlysed or nucleated red blood cells in the gate.
- a TruCOUNT Tube was labelled with the sample identification number.
- 20 ⁇ L of TriTEST CD3/CD16+CD56/CD45 reagent was pipetted into the bottom of the tube.
- 50 ⁇ L of well-mixed, anticoagulated whole blood was pipetted into the bottom of the tube.
- Anticoagulated blood (EDTA) stored at room temperature (20-25° C.) must be stained within 24 hours of draw and analyzed within 6 hours of staining (keep at room temperature and protected from light).
- the tube was vortexed gently to mix.
- the tube was incubated for 15 minutes in the dark at room temperature (20-25° C.).
- 450 ⁇ L 1 ⁇ FACS Lysing Solution was added to the tube.
- the tube was vortexed and incubated again for 15 minutes in the dark at room temperature (20-25° C.).
- TruCOUNT Tubes a known volume of sample is stained directly in a TruCOUNT Tube.
- the lyophilized pellet in the tube dissolves, releasing a known number of fluorescent beads.
- the absolute number (cells/ ⁇ L) of positive cells in the sample can be determined by comparing cellular events to bead events.
- the cells were vortexed thoroughly (at low speed) to reduce aggregation before running them on the flow cytometer.
- the CD45 vs SSC dot plot was visually inspected. Lymphocytes appear as a bright, compact cell population with low to moderate SSC. Monocytes (M) and granulocytes (G) appear as distinct populations. Analysis was completed when the cell populations of monocytes and lymphocytes showed clear separation.
- Lymphocytes were first gated as CD45 positive, low SSC cell population.
- CD16/CD56 vs CD3 were pre-selected.
- T-cells (T) should appear as a compact bright CD3 positive cluster.
- NK-cells (NK) should appear as a compact bright CD16/CD56 positive cluster. Gating was completed and the T, and NK cells were counted.
- Bead event counts were done using a CD16/CD56 vs CD3 plot without any pre-selected gate. Beads should appear as a PE/FITC double positive cluster.
- the absolute number (cells/ ⁇ L blood) of T cells or NK cells in the sample was determined by comparing cellular events to bead events. Either MultiSET software or manual (using CellQuest or other software) data analysis was done. For manual counting, the number (#) of positive cellular acquired events was divided by the number (#) of acquired bead events, then multiplied by the (total TruCOUNT bead count (lot dependent) divided by whole blood sample volume of 50 ⁇ L). The result is absolute cell numbers per microliter.
- TruCOUNT ⁇ ⁇ beads 50 ⁇ ⁇ ⁇ ⁇ ⁇ l ⁇ ⁇ whole ⁇ ⁇ blood # ⁇ ⁇ cells / ⁇ ⁇ ⁇ l ⁇ ⁇ blood
- CD16 an exploratory biomarker was quanitified on peripheral NK Cells centrally by ICON Central Laboratories (Farmingdale, N.Y.).
- CD45 AmCyan (Clone 2D1, BD Biosciences, Cat #339192); CD3 FITC (Clone UCHT1, BioLegend, Cat #300406); Mouse IgG FITC (Clone MOPC-21, BioLegend, Cat #400110); CD16 PE (Clone 3G8, BioLegend, Cat #302008); MOR00208; Mouse IgG PE (Clone MOPC-21, BioLegend, Cat #400114); CD56 PerCP-Cy5.5 (Clone HCD56, BioLegend, Cat #318322); and Mouse IgG PerCP-Cy5.5 (Clone MOPC-21, BioLegend, Cat #400150).
- the tubes were centrifuged at 300 ⁇ g for 10 min at 4° C. and supernatant removed. The t ubes were vortexed to resuspend cell pellet. The cell pellet was washed with DBPS, centrifuged, supernatant removed and resuspended by vortexing. The washed PBMC suspension was added into an eppendorf tube containing 1 ⁇ L ViViD stock solution; incubated for 15 min on ice and kept in dark (cover with aluminum foil). The stained ViViD PBMC were transferred into a new labeled conical tube and then ice cold FACS Buffer was added. The cells were centrifuged and vortexed again for resuspension.
- Polystyrene falcon tubes were labeled for each sample (Table 1).
- the antibodies or isotype control antibodies were added to the appropriate tubes.
- the aliquot of ViViD stained PBMCs was added to each tube (Table 1).
- the tubes were vortexed and incubate.
- FACS Buffer was added and the cells were centrifuged and vortexed again for resuspension.
- BD Pharm Lyse Lysing Buffer was added, and the cells were vortexed, centrifuge and aspirated to remove supernatant and vortexed again to resuspend.
- FACS Buffer was added again and the cells were centrifuged and vortexed again for resuspension.
- One site of measurable disease by magnetic resonance imaging (MRI) or computed tomography (CT) scan defined as at least one lesion that measures at least 1.5 ⁇ 1.5 cm, with the exception:
- MRI magnetic resonance imaging
- CT computed tomography
- Laboratory criteria at screening a) Absolute neutrophil count (ANC) ⁇ 1.0 (1000/mm3) b) Platelet count ⁇ 75 ⁇ 109/L without previous transfusion within 10 days of first study drug administration. c) Haemoglobin ⁇ 8.0 g/dL (may have been transfused). d) Serum creatinine ⁇ 2.0 ⁇ upper limit of normal (ULN). e) Total bilirubin ⁇ 2.0 ⁇ ULN. f) Alanine transaminase (ALT) and aspartate aminotransferase (AST) ⁇ 2.5 ⁇ ULN.
- CNS central nervous system
- MOR00208 was given at a dose of 12 mg/kg on days 1, 8, 15, and 22. At the end of the two cycles, patients having Stable Disease or better were treated with a third 28 day cycle applying the same dosing and schedule as the first two cycles. At the end of the third cycle, patients having Partial Response or better went into Maintenance. In Maintanence, MOR00208 was given at a dose of 12 mg/kg every 14 or 28 days until disease progression.
- iNHL means a heterogeneous group of not further specified indolent, not aggressive, NHL types, e.g. Marginal Cell Lymphoma, Marginal Zone Lymphoma, and Mucosa associated lymphoid tissue (MALT) lymphoma.
- NHL types e.g. Marginal Cell Lymphoma, Marginal Zone Lymphoma, and Mucosa associated lymphoid tissue (MALT) lymphoma.
- DCR disease control rate
- DLBCL diffuse large B-cell lymphoma
- iNHL indolent non-Hodgkin's lymphoma
- MCL mantel cell lymphoma' ORR, overall response rate.
- DCR (CR+PR+SD) was considered the most relevant efficacy endpoint the analysis of patient characteristic and biomarkers in this trial as the majority of patients with SD had marked target lesion reduction but as per study design were not treated beyond cycle 3. Accordingly, patients having SD included in the analysis.
- Example 1 and Example 2 above were used to evaluate the baseline peripheral NK cell counts, T cell counts and baseline CD16 expression on peripheral NK cells. The data is shown in Table 2.
- ROC Receiver Operating Characteristic
- the area under the curve measures the performance of a classifier and is frequently applied for method comparison. A higher AUC means a better classification.
- the AUC for peripheral NK/T cell counts and for CD16 expression on NK cells is 0.66, 0.53 and 0.61 respectively ( FIGS. 3, 4 and 5 ).
- the determination of the cut off depends on the objective the respective method is directed to.
- Various criteria such as maximum accuracy, maximum diagnostic odds ratio, minimal error rate, maximum sensitivity and/or maximum specificity would lead to a different determination of the cut off.
- a balance between more of such criteria, e.g. sensitivity and specificity would also lead to a specific determination of the cut off.
- the AUC is 0.53 and the ROC curve is close to the bisectrix at any value of specificity and sensitivity therefore even selecting a different cut off than 500 cell// ⁇ l had no impact on the negative results of the DCR and PFS subgroup analysis.
- the determination of the cut off can be balanced either in favor of sensitivity or specificity. If even more weight is assigned to sensitivity for the identification of the optimal cut-off the method would be different and a lower cut-off for the NK cell count is contemplated. In such case a cut off of at least 50 NK cells/ ⁇ l is determined. Alternatively, a cut off of at least 60 NK cells/ ⁇ l, at least 70 NK cells/ ⁇ l, at least 80 NK cells/ ⁇ l, at least 90 NK cells/ ⁇ l or at least 100 NK cells/ ⁇ l is determined.
- the cut-off for the NK cell count is increased and is determined between at least 100 NK cells/ ⁇ l up to at least 150 NK cells/ ⁇ l. Therefore for maximizing the specificity a cut off of at least 100 NK cells/ ⁇ l, at least 110 NK cells/ ⁇ l, at least 120 NK cells/ ⁇ l, at least 130 NK cells/ ⁇ l, at least 140 NK cells/ ⁇ l or at least 150 NK cells/ ⁇ l is selected.
- DCR Disease Control Rate
- PR Partial Response
- SD Stable Disease
- PFS Progression Free Survival
- the PFS comparing patients having NK cell counts having at least 100 cells/ ⁇ l as compared to patients having lower NK cell counts showed a statistically significant difference with a HR of 0.1561 (unadjusted log-rank p value 0.0003). This further confirms the predictivity of NK cells counts in the response of patients treated with MOR00208 of those patients having CLL, NHL, ALL or SLL.
Abstract
Description
- The present disclosure is directed to identifying characteristics and biomarkers in patients that benefit from treatment with anti-CD19 antibodies.
- CD19 is a 95-kDa transmembrane glycoprotein of the immunoglobulin superfamily containing two extracellular immunoglobulin-like domains and an extensive cytoplasmic tail. The protein is a pan-B lymphocyte surface receptor and is ubiquitously expressed from the earliest stages of pre-B cell development onwards until it is down-regulated during terminal differentiation into plasma cells. It is B-lymphocyte lineage specific and not expressed on hematopoietic stem cells and other immune cells, except some follicular dendritic cells. CD19 functions as a positive regulator of B cell receptor (BCR) signaling and is important for B cell activation and proliferation and in the development of humoral immune responses. It acts as a co-stimulatory molecule in conjunction with CD21 and CD81 and is critical for B cell responses to T-cell-dependent antigens. The cytoplasmic tail of CD19 is physically associated with a family of tyrosine kinases that trigger downstream signaling pathways via the src-family of protein tyrosine kinases. CD19 is an attractive target for cancers of lymphoid origin since it is highly expressed in nearly all chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphomas (NHL), as well as many other different types of leukemias, including acute lymphocytic leukemia (ALL) and hairy cell leukemia (HCL).
- The clinical development of CD19 directed antibodies had previously been limited by the internalization of the CD19 antigen, however, improved antibody modification technology has restored this potential therapeutic target. MOR00208 (previously named XmAb5574) is an Fc engineered humanized monoclonal antibody that binds CD19. The increase in binding of MOR00208 Fc to FcγR, due to XmAb engineered mutations, significantly enhances in-vitro antibody dependent cell-mediated cytotoxicity (ADCC), antibody dependent cell-mediated phagocytosis (ADCP), and direct cytotoxic effects (apoptosis) on tumor relative to the unmodified antibody. MOR00208 has not been shown to mediate complement dependent cytotoxicity.
- MOR00208 has or is currently being studied in clinical trials in CLL, ALL and NHL. Specifically, a Phase I trial titled Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia, and a Phase Ila trial titled Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to treat B-cell Acute Lymphoblastic Leukemia (B-ALL) are completed. A Phase Ila trial titled Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL) has completed recruitment. And the following trials are planned/ongoing: a Phase II/III trial titled A Trial to Evaluate the Efficacy and Safety of MOR00208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (B-MIND), a Phase II trial titled Study to Evaluate Efficacy and Safety of MOR00208 With Idelalisib in R/R CLL/SLL Patients Pretreated With BTKi, a Phase II trial titled A Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL, and a Phase II trial titled Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL. In a further current Phase II trial (COSMOS) the Efficacy and Safety of MOR00208 in combination with idelalisib or venetoclax in Patients with Relapsed or Refractory CLL, SLL is studied.
- Single agent efficacy of MOR00208 has been reported in CLL, and NHL. The general variable response rates of patients to monoclonal antibody therapies, however, indicate that methods are needed to accurately predict which patients are likely to respond to such antibody therapies so that the treatment can be administered to those patients who are most likely to receive benefits. Particular biomarkers or characteristics of patients may be found for which a particular concentration or range for each biomarker correlates with responsiveness to such therapy.
- The influence of natural killer (NK) cell count on the survival of patients with DLBCL treated with Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride (Hydroxydaunomycin), Vincristine Sulfate (Oncovin) and Prednisone (R-CHOP) was evaluated. Kim et al., Blood Research, 49:3, 162-169 (September 2014). Previously, it was reported that peripheral NK cell count was associated with clinical outcome in patients with aalPl 2-3 DLBCL. Plonquet et al., Ann Oncol 2007; 18:1209-15.
- It is clear that significant efforts and investment are needed to discover and identify such patient characteristics and biomarkers predictive of efficacy.
- MOR00208 has been studied in patients having CLL, ALL, NHL and SLL. Accordingly, a thorough analysis of clinical data has been completed to date in order to identify characteristics or biomarkers of patients that are more likely to benefit from MOR00208 treatment.
- MOR00208 specifically targets the CD19 surface antigen and mediates direct tumor cell killing via its enhanced ADCC effector function. In preclinical studies, MOR00208 has been shown to significantly enhance in vitro ADCC, ADCP, and direct cytotoxic effects (apoptosis) on CD19+ tumor cell lines spanning a broad range of human lymphomas and leukemias (Burkitt's lymphoma, CLL, hairy cell leukemia (HCL), CD19+ chronic myeloid leukemia (CML), diffuse large B cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL), expressing levels of CD19 antigen ranging from 15,000 to 105,000 molecules/cell. Similar effects have also been observed in relation to freshly isolated patient CLL or ALL cells and are also expected to translate to primary non-Hodgkin's lymphoma (NHL) cells since the expression range reported for ALL and CLL B cells covers the range observed for NHL B cells (Ginaldi et al., 1998; Olejniczak et al., 2006). Based on the widely and homogenous surface expression of CD19 throughout various types of B cell neoplasms the effect of MOR00208 in the present study can be transferred to a broad range of human lymphomas and leukemias, such as CLL, ALL, NHL and SLL and subtypes thereof.
- Data from the Phase Ila trial titled Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL) has been thoroughly analyzed. As a result of these efforts, the following disclosure provides characteristics and biomarkers of patients where anti-CD19 antibodies are efficacious.
- Specifically at least the following characteristics of patients were evaluated: a) age, b) gender, c) if patients had received a dose of Rituximab within the last 6 months, d) whether the patients were Rituximab refractory, e) whether patients have the FCgammaRIIIa high or low affinity allele, f) whether patients have the FCgammaRIIa high or low affinity allele, g) whether patients had a duration of response to the previous treatment of greater than 12 months, h) baseline peripheral T cell counts (cells/μl), i) baseline peripheral NK cell count (cells/μl) and j) baseline CD16 expression on peripheral NK cells (Antibodies Bound per Cells—ABCs).
- Both 1) baseline peripheral NK cell counts and 2) baseline CD16 expression on peripheral NK cells showed clear correlations to patient responses with MOR00208 therapy. Specifically, patients having a higher baseline peripheral NK cell count per μl correlated with a higher Disease Control Rate (DCR). DCR includes patients have Complete Response (CR)+Partial Response (PR)+Stable Disease (SD). Additionally, such patients had a significantly better Progression Free Survival (PFS) as compared to patients having lower NK cells counts. In addition, patients having a baseline CD16 expression on NK cells of at least 60,000 (ABCs) correlated with higher Disease Control Rate (DCR).
- Therefore, patients diagnosed with CLL, ALL, NHL and SLL and having either a) a high peripheral NK cell count or 2) baseline CD16 expression on peripheral NK cells of at least 60,000 ABCs are more likely to benefit from MOR00208 treatment.
- Both 1) baseline peripheral NK cell counts and 2) baseline CD16 expression on peripheral NK cells showed clear correlations to patient responses with MOR00208 therapy. Specifically, patients having a baseline peripheral NK cell count of at least 50 cells/μl correlated with a higher Disease Control Rate (DCR). DCR includes patients have Complete Response (CR)+Partial Response (PR)+Stable Disease (SD). Additionally, patients having a baseline NK cell count of at least 50 cells/μl had a significantly better Progression Free Survival (PFS) as compared to patients having lower NK cells counts. In addition, patients having a baseline CD16 expression on NK cells of at least 60,000 (ABCs) correlated with higher Disease Control Rate (DCR).
- Therefore, patients diagnosed with CLL, ALL, NHL and SLL and having either a) baseline peripheral NK cell count of at least 50 cells/μl or 2) baseline CD16 expression on peripheral NK cells of at least 60,000 ABCs are more likely to benefit from MOR00208 treatment.
- Both 1) baseline peripheral NK cell counts and 2) baseline CD16 expression on peripheral NK cells showed clear correlations to patient responses with MOR00208 therapy. Specifically, patients having a baseline peripheral NK cell count of at least 100 cells/μl correlated with a higher Disease Control Rate (DCR). DCR includes patients have Complete Response (CR)+Partial Response (PR)+Stable Disease (SD). Additionally, patients having a baseline NK cell count of at least 100 cells/μl had a significantly better Progression Free Survival (PFS) as compared to patients having lower NK cells counts. In addition, patients having a baseline CD16 expression on NK cells of at least 60,000 (ABCs) correlated with higher Disease Control Rate (DCR).
- Therefore, patients diagnosed with CLL, ALL, NHL and SLL and having either a) baseline peripheral NK cell count of at least 100 cells/μl or 2) baseline CD16 expression on peripheral NK cells of at least 60,000 ABCs are more likely to benefit from MOR00208 treatment.
-
FIG. 1 shows the amino acid sequences of MOR00208 variable domains and CDRs. -
FIG. 2 shows the amino acid sequences of MOR00208′s full heavy and light chains. -
FIG. 3 shows the Receive Operating Characteristic (ROC) analysis of peripheral NK cell counts as a predictor for DCR. -
FIG. 4 shows the ROC analysis of CD16 expression levels on peripheral NK cells (ABCs) as a predictor for DCR. -
FIG. 5 shows the ROC analysis of peripheral T cell count as a potential predictor for DCR. -
FIG. 6 shows that peripheral NK cell counts and CD16 expression levels on peripheral NK cells are independent variables and not correlated. -
FIG. 7 shows the Forest Plot with DCRs in patient subgroups with specific baseline characteristics and biomarkers -
FIG. 8 shows the progression free survival difference between patients having at least 100 cells/μl peripheral NK cell counts versus patients having lower NK cell counts. -
FIG. 9 shows the progression free survival difference between patients having at least 60,000 ABCs in CD16 expression on peripheral NK cells versus patients having lower CD16 expression on NK cells. -
FIG. 10 shows the progression free survival difference between patients having at least 500 cells/μl peripheral T cell counts versus patients having lower T cell counts. - The term “antibody” means monoclonal antibodies, including any isotype, such as, IgG, IgM, IgA, IgD and IgE. An IgG antibody is comprised of two identical heavy chains and two identical light chains that are joined by disulfide bonds. Each heavy and light chain contains a constant region and a variable region. Each variable region contains three segments called “complementarity-determining regions” (“CDRs”) or “hypervariable regions”, which are primarily responsible for binding an epitope of an antigen. They are referred to as CDR1, CDR2, and CDR3, numbered sequentially from the N-terminus. The more highly conserved portions of the variable regions outside of the CDRs are called the “framework regions”. An “antibody fragment” means an Fv, scFv, dsFv, Fab, Fab′ F(ab′)2 fragment, or other fragment, which contains at least one variable heavy or variable light chain, each containing CDRs and framework regions.
- “VH” refers to the variable region of an immunoglobulin heavy chain of an antibody, or antibody fragment. “VL” refers to the variable region of the immunoglobulin light chain of an antibody, or antibody fragment.
- “Fc region” means the constant region of an antibody, which in humans may be of the IgG1, 2, 3, 4 subclass or others. The sequences of human Fc regions are available at IMGT, Human IGH C-REGIONs, www.imgt.org/IMGTrepertoire/Proteins/protein/human/IGH/IGHC/Hu_IGHCallgenes.html (retrieved on 16 May 2011).
- The term patient includes a human.
- NHL is a heterogeneous malignancy originating from lymphocytes. In the United States (U.S.), the incidence is estimated at 65,000/year with mortality of approximately 20,000 (American Cancer Society, 2006; and SEER Cancer Statistics Review). The disease can occur in all ages, the usual onset begins in adults over 40 years, with the incidence increasing with age. NHL is characterized by a clonal proliferation of lymphocytes that accumulate in the lymph nodes, blood, bone marrow and spleen, although any major organ may be involved. The current classification system used by pathologists and clinicians is the World Health Organization (WHO) Classification of Tumours, which organizes NHL into precursor and mature B-cell or T-cell neoplasms. The PDQ is currently dividing NHL as indolent or aggressive for entry into clinical trials. The indolent NHL group is comprised primarily of follicular subtypes, small lymphocytic lymphoma, MALT (mucosa-associated lymphoid tissue), and marginal zone; indolent encompasses approximately 50% of newly diagnosed B-cell NHL patients. Aggressive NHL includes patients with histologic diagnoses of primarily diffuse large B cell (DLBL, DLBCL, or DLCL) (40% of all newly diagnosed patients have diffuse large cell), Burkitt's, and mantle cell. The clinical course of NHL is highly variable. A major determinant of clinical course is the histologic subtype. Most indolent types of NHL are considered to be incurable disease. Patients respond initially to either chemotherapy or antibody therapy and most will relapse. Studies to date have not demonstrated an improvement in survival with early intervention. In asymptomatic patients, it is acceptable to “watch and wait” until the patient becomes symptomatic or the disease pace appears to be accelerating. Over time, the disease may transform to a more aggressive histology. The median survival is 8 to 10 years, and indolent patients often receive 3 or more treatments during the treatment phase of their disease. Initial treatment of the symptomatic indolent NHL patient historically has been combination chemotherapy. The most commonly used agents include: cyclophosphamide, vincristine and prednisone (CVP); or cyclophosphamide, adriamycin, vincristine, prednisone (CHOP). Approximately 70% to 80% of patients will respond to their initial chemotherapy, duration of remissions last on the order of 2-3 years. Ultimately the majority of patients relapse. The discovery and clinical use of the anti-CD20 antibody, rituximab, has provided significant improvements in response and survival rate. The current standard of care for most patients is rituximab+CHOP (R-CHOP) or rituximab+CVP (R-CVP). Interferon is approved for initial treatment of NHL in combination with alkylating agents, but has limited use in the U.S. Rituximab therapy has been shown to be efficacious in several types of NHL, and is currently approved as a first line treatment for both indolent (follicular lymphoma) and aggressive NHL (diffuse large B cell lymphoma). However, there are significant limitations of anti-CD20 monoclonal antibody (mAb), including primary resistance (50% response in relapsed indolent patients), acquired resistance (50% response rate upon re-treatment), rare complete response (2% complete resonse rate in relapsed population), and a continued pattern of relapse. Finally, many B cells do not express CD20, and thus many B-cell disorders are not treatable using anti-CD20 antibody therapy.
- In addition to NHL there are several types of leukemias that result from dysregulation of B cells. Chronic lymphocytic leukemia (also known as “chronic lymphoid leukemia” or “CLL”), is a type of adult leukemia caused by an abnormal accumulation of B lymphocytes. In CLL, the malignant lymphocytes may look normal and mature, but they are not able to cope effectively with infection. CLL is the most common form of leukemia in adults. Men are twice as likely to develop CLL as women. However, the key risk factor is age. Over 75% of new cases are diagnosed in patients over
age 50. More than 10,000 cases are diagnosed every year and the mortality is almost 5,000 a year (American Cancer Society, 2006; and SEER Cancer Statistics Review). CLL is an incurable disease but progresses slowly in most cases. Many people with CLL lead normal and active lives for many years. Because of its slow onset, early-stage CLL is generally not treated since it is believed that early CLL intervention does not improve survival time or quality of life. Instead, the condition is monitored over time. Initial CLL treatments vary depending on the exact diagnosis and the progression of the disease. There are dozens of agents used for CLL therapy. Combination chemotherapy regimens such as FCR (fludarabine, cyclophosphamide and rituximab), and BR (Ibrutinib and rituximab) are effective in both newly-diagnosed and relapsed CLL. Allogeneic bone marrow (stem cell) transplantation is rarely used as a first-line treatment for CLL due to its risk. - Another type of leukemia is Small lymphocytic lymphoma (SLL) that is considered a CLL variant that lacks the clonal lymphocytosis required for the CLL diagnosis, but otherwise shares pathological and immunophenotypic features (Campo et al., 2011). The definition of SLL requires the presence of lymphadenopathy and/or splenomegaly. Moreover, the number of B lymphocytes in the peripheral blood should not exceed 5×109/L. In SLL, the diagnosis should be confirmed by histopathologic evaluation of a lymph node biopsy whenever possible (Hallek et al., 2008). The incidence of SLL is approximately 25% of CLL in the US (Dores et al., 2007).
- Another type of leukemia is acute lymphoblastic leukemia (ALL), also known as acute lymphocytic leukemia. ALL is characterized by the overproduction and continuous multiplication of malignant and immature white blood cells (also known as lymphoblasts) in the bone marrow. ‘Acute’ refers to the undifferentiated, immature state of the circulating lymphocytes (“blasts”), and that the disease progresses rapidly with life expectancy of weeks to months if left untreated. ALL is most common in childhood with a peak incidence of 4-5 years of age. Children of age 12-16 die more easily from it than others. Currently, at least 80% of childhood ALL are considered curable. Under 4,000 cases are diagnosed every year and the mortality is almost 1,500 a year (American Cancer Society, 2006; and SEER Cancer Statistics Review).
- The use of a CD19 antibody in non-specific B cell lymphomas is discussed in WO2007076950 (US2007154473), which are both incorporated by reference. The use of a CD19 antibody in CLL, NHL and ALL is described in Scheuermann et al., CD19 Antigen in Leukemia and Lymphoma Diagnosis and Immunotherapy, Leukemia and Lymphoma, Vol. 18, 385-397 (1995), which is incorporated by reference in its entirety.
- Additional antibodies specific for CD19 are described in WO2005012493 (U.S. Pat. No. 7,109,304), WO2010053716 (U.S. Ser. No. 12/266,999) (Immunomedics); WO2007002223 (U.S. Pat. No. 8,097,703) (Medarex); WO2008022152 (Ser. No. 12/377,251) and WO2008150494 (Xencor), WO2008031056 (U.S. Ser. No. 11/852,106) (Medimmune); WO 2007076950 (U.S. Ser. No. 11/648,505) (Merck Patent GmbH); WO 2009/052431 (U.S. Ser. No. 12/253,895) (Seattle Genetics); and WO2010095031 (Ser. No. 12/710,442) (Glenmark Pharmaceuticals), WO2012010562 and WO2012010561 (International Drug Development), WO2011147834 (Roche Glycart), and WO 2012/156455 (Sanofi), which are all incorporated by reference in their entireties.
- The term “CD19” refers to the protein known as CD19, having the following synonyms: B4, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, CVID3, Differentiation antigen CD19, MGC12802, and T-cell surface antigen Leu-12.
- Human CD19 has the amino acid sequence of:
-
(SEQ ID NO: 7) MPPPRLLFFLLFLTPMEVRPEEPLVVKVEEGDNAVLQCLKGTSDGPTQQL TWSRESPLKPFLKLSLGLPGLGIHMRPLAIWLFIFNVSQQMGGFYLCQPG PPSEKAWQPGWTVNVEGSGELFRWNVSDLGGLGCGLKNRSSEGPSSPSGK LMSPKLYVWAKDRPEIWEGEPPCLPPRDSLNQSLSQDLTMAPGSTLWLSC GVPPDSVSRGPLSWTHVHPKGPKSLLSLELKDDRPARDMWVMETGLLLPR ATAQDAGKYYCHRGNLTMSFHLEITARPVLWHWLLRTGGWKVSAVTLAYL IFCLCSLVGILHLQRALVLRRKRKRMTDPTRRFFKVTPPPGSGPQNQYGN VLSLPTPTSGLGRAQRWAAGLGGTAPSYGNPSSDVQADGALGSRSPPGVG PEEEEGEGYEEPDSEEDSEFYENDSNLGQDQLSQDGSGYENPEDEPLGPE DEDSFSNAESYENEDEELTQPVARTMDFLSPHGSAWDPSREATSLGSQSY EDMRGILYAAPQLRSIRGQPGPNHEEDADSYENMDNPDGPDPAWGGGGRM GTWSTR. - “MOR00208” is an anti-CD19 antibody. The amino acid sequence of the variable domains is provided in
FIG. 1 . The amino acid sequence of the heavy and light chain Fc regions of MOR00208 are provided inFIG. 2 . “MOR00208” and “XmAb 5574” are used as synonyms to describe the antibody shown inFIGS. 1 and 2 . The MOR00208 antibody is described in U.S. patent application Ser. No. 12/377,251, which is incorporated by reference in its entirety. - U.S. patent application Ser. No. 12/377,251 describes the antibody named 4G7 H1.52 Hybrid S239D/I332E/4G7 L1.155 (later named MOR00208) as follows:
-
>4G7 H1.52 Hybrid S239D/I332E (SEQ ID NO: 8) EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGY INPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGT YYYGTRVFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ TYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPDVFLFPPK PKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQF NSTFRVVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKTISKTKGQPREP QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP MLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG K >4G7 L1.155 (SEQ ID NO: 9) DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQ LLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYP ITFGAGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK VQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE VTHQGLSSPVTKSFNRGEC - A pharmaceutical composition includes an active agent, e.g. an antibody for therapeutic use in humans. A pharmaceutical composition may additionally include pharmaceutically acceptable carriers or excipients.
- “Administered” or “administration” refers to the delivery of a pharmaceutical composition by an injectable form, such as, for example, an intravenous, intramuscular, intradermal or subcutaneous route or mucosal route, for example, as a nasal spray or aerosol for inhalation or as an ingestable solution, capsule or tablet.
- The antibody which is administered according to the present disclosure is administered to the patient in a therapeutically effective amount. A “therapeutically effective amount” refers to an amount sufficient to provide some improvement of the clinical manifestations of a given disease or disorder. As an example, patients in the exemplified study received dosing of MOR00208 at 12 mg/kg once weekly, and in maintenance once every two weeks or monthly.
- The amount that is effective for a particular therapeutic purpose will depend on the severity of the disease or injury as well as on the weight and general state of the subject. It will be understood that determination of an appropriate dosage may be achieved, using routine experimentation, by constructing a matrix of values and testing different points in the matrix, all of which is within the ordinary skills of a trained physician or clinical scientist.
- Baseline means prior to administration of the desired therapy. For example, prior to administration of the desired anti-CD19 antibody.
- A receiver operating characteristic (ROC) analysis was used to analyze the predictivity, sensitivity, specifity and to determine the cut-offs for potential biomarkers, such as NK cell counts, CD16 expression levels on NK cells, and T cells counts. The following additional methods exist for estimating an optimal cut-off: “Max.Accuracy”—the cut-off which maximize the accuracy; b) “Max.DOR”—the cut-off which maximize the diagnostic odds ratio; c) “Error.rate”—the cut-off which minimizes the error rate; d) “Max.Accuracy.area”—the cut-off which maximize the accuracy area; e) “Max.Sens+Spec”—the cut-off which maximize the sum of sensitivity with specificity; f) “Max.Youden”—the cut-off which maximize the Youden index; g) “Se=Sp”—the cut-off which Sensitivity is equal to Specificity; h) “Min.ROC.Dist”—the cut-off which minimize the distance between the curve and the upper left corner of the graph; i) “Max.Efficiency”—the cut-off which maximize the efficiency; and j) “Min.MCT”—the cut-off which minimize the misclassification cost term. See Lopez-Raton, M., Rodriguez-Alvarez, M. X, Cadarso-Suarez, C. and Gude-Sampedro, F. (2014). Optimal Cutpoints: An R Package for Selecting Optimal Cutpoints in Diagnostic Tests. Journal of Statistical Software 61(8), 1-36.
- Antibodies specific to CD19 have also been tested preclinically in combination with other drugs. For example, MOR00208 had been tested in combination with nitrogen mustards, purine analogs, thalidomide analogs, phosphoinositide 3-kinase inhibitor, BCL-2 inhibitors and bruton's tyrosine kinase (BTK) inhibitors.
- A “nitrogen mustard” is a nonspecific DNA alkylating agent used as chemotherapy. Alkylating agents add an alkyl group (CnH2n+1) to nucleic acid bases, e.g., adding an alkyl group to the guanine base of DNA at the
number 7 nitrogen atom of the imidazole ring. The alkylation steps result in the formation of interstrand cross-links (ICLs). These ICLs are highly cytotoxic, since they block fundamental metabolic processes such as replication and transcription. Nitrogen mustards include cyclophosphamide, chlorambucil, uramustine, ifosfamide, melphalan and bendamustine. - Bendamustine is marketed under the names Ribomustin®,and Treanda®, and is also known as SDX-105, by Mundipharma International Corporation Limited (Licensee of Astellas Pharma GmbH) and Cephalon for the treatment of chronic lymphocytic leukemias (CLL), indolent B-cell non-Hodgkin's lymphoma (NHL), and other lymphomas. Bendamustine has the following structure:
- A purine analog is an antimetabolite, which mimics the structure of metabolic purines, thereby interfering with the synthesis of nucleic acids. Fludarabine, for example, may be incorporated into RNA and DNA by substituting for the purine nucleotides, adenine and guanine. Purine analogs inhibit growth of fast proliferating cells of an individual, e.g. cancer cells, bone marrow cells or cells present in the gastrointestinal tract. Purine analogs include mercaptopurine, azathioprine, thioguanine and fludarabine. Fludarabine or fludarabine phosphate (Fludara®) is a chemotherapy drug used in the treatment of chronic lymphocytic leukemia and indolent non-Hodgkins lymphomas. Fludarabine is a purine analog. Fludarabine inhibits DNA synthesis by interfering with ribonucleotide reductase and DNA polymerase and is S phase-specific (since these enzymes are highly active during DNA replication). Fludarabine has the following structure:
- A “thalidomide analog” includes, but is not limited to, thalidomide itself, lenalidomide (CC-5013, Revlimid™), Pomalidomide (CC4047, Actimid™) and the compounds disclosed in WO2002068414 and WO2005016326, which are incorporated by reference in their entireties. The term refers to a synthetic chemical compound using the thalidomide structure as a backbone (e.g., side groups have been added or such groups have been deleted from the parent structure). The analog differs in structure from thalidomide and its metabolite compounds such as by a difference in the length of an alkyl chain, a molecular fragment, by one or more functional groups, or a change in ionization. The term “thalidomide analog” also includes the metabolites of thalidomide. Thalidomide analogs include the racemic mixture of the S- and the R-enantiomer of a respective compound and the S-enantiomer or to the R-enantiomer individually. The racemic mixture is preferred.
- Thalidomide analogs include the compounds of the following structures:
-
- A “phosphoinositide 3-kinase inhibitor” is a class of medical drug that functions by inhibiting one or more of the phosphoinositide 3-kinase enzymes, which are part of the PI3K/AKT/mTOR pathway, an important signalling pathway for many cellular functions such as growth control, metabolism and translation initiation.
- There are a number of different classes and isoforms of PI3Ks.
Class 1 PI3Ks have a catalytic subunit known as p110, with four types (isoforms)—p110 alpha, p110 beta, p110 gamma and p110 delta. Current inhibitors being studied inhibit one or more isoforms of the class I PI3Ks. - Phosphoinositide 3-kinase inhibitors include at least Idelalisib, Duvelisib and Copanlisib. Idelalisib is marketed by Gilead Sciences, Inc. (trade name Zydelig, also named GS-1101 or CAL-101). Idelalisib is is currently labelled for the treatment of relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities; relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies; relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies. The substance acts as a phosphoinositide 3-kinase inhibitor; more specifically, it blocks P110δ, the delta isoform of the enzyme phosphoinositide 3-kinase.
- The formula of Idelalisib is:
- A “Bruton's tyrosine kinase (BTK) inhibitor” is a class of drug that functions by inhibiting the tyrosine-protein kinase BTK enzyme, which plays an important role in B-cell development. Specifically, BTK contains a PH domain that binds phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3 binding induces Btk to phosphorylate phospholipase C, which in turn hydrolyzes PIP2, a phosphatidylinositol, into two second messengers, inositol triphosphate (IP3) and diacylglycerol (DAG), which then go on to modulate the activity of downstream proteins during B-cell signalling.
- Bruton's tyrosine kinase (BTK) inhibitors include Ibrutinib. Ibrutinib is marketed by Pharmacyclics, Inc and Johnson & Johnson's Janssen Pharmaceutical (trade name Imbruvica, also named PCI-32765). Ibrutinib is currently labelled for the treatment of patients with Mantle cell lymphoma (MCL) who have received at least one prior therapy, Chronic lymphocytic leukemia (CLL) who have received at least one prior therapy, Chronic lymphocytic leukemia with 17p deletion, and Waldenstrom's macroglobulinemia. The formula of Ibrutinib is 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one and has the following structure:
- A “BCL-2 inhibitor” is a class of drug that functions by inhibiting anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein, leading to programmed cell death of cells. BCL-2 inhibitor include venetoclax. Venetoclax is marketed by Abbvie and Genentech (trade name VENCLEXTA™, also known as GDC-0199, ABT-199, and RG7601). Venetoclax is currently labelled for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy. The formula of venetoclax is 4-(4-{[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]nethyl}-1-piperazinyl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide and has the following structure:
- “Venetoclax,” “ABT”, and “ABT-199” are used as synonyms herein.
- An aspect is a method of identifying a subject having chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) or small lymphocytic lymphoma (SLL) that is responsive to treatment with an anti-CD19 antibody, said method comprising:
-
- a. providing a sample obtained from said subject prior to treatment with said anti-CD19 antibody,
- b. determining the level of at least one biomarker in said sample selected from the group consisting of:
- i. peripheral NK cell count, and
- ii. CD16 expression levels on peripheral NK cells,
- c. comparing the level of said at least one biomarker in said sample to a predetermined cut off level,
- wherein levels of said at least one biomarker at or above the predetermined cut off level is indicative of a subject who would benefit from treatment with an anti-CD19 antibody.
- In embodiments, the sample is a blood sample. In embodiments, said sample comprises peripheral NK cells.
- In embodiments, the predetermined cut off level of said biomarker is a baseline peripheral NK cell count of at least 50 cells/μl, at least 75 cells/μl, at least 100 cells/μl, at least 125 cells/μl, at least 150 cells/μl, at least 175 cells/μl, at least 200 cells/μl, at least 225 cells/μl, or at least 250 cells/μl. In embodiments, the predetermined cut off level of said biomarker is baseline CD16 expression levels on peripheral NK cells of at least 45,000 ABCs, at least 60,000 ABCs, at least 75,000 ABCs, or at least 90,000 ABCs.
- In embodiments, the predetermined cut off of said biomarker is:
-
- a. a baseline peripheral NK cell count of at least 50 cells/μl, or
- b. baseline CD16 expression levels on peripheral NK cells of at least 60,000 (ABCs).
- In embodiments, the predetermined cut of said biomarker is:
-
- a. baseline peripheral NK cell count of at least 50 cells/μl, and
- b. baseline CD16 expression levels on peripheral NK cells of at least 60,000 (ABCs).
- In embodiments, predetermined cut off level a baseline peripheral NK cell count of at least 50 cells/μl. In embodiments, the predetermined cut of said biomarker is baseline CD16 expression levels on peripheral NK cells of at least 60,000 (ABCs).
- In embodiments, the predetermined cut off of said biomarker is:
-
- a. a baseline peripheral NK cell count of at least 70 cells/μl, or
- b. baseline CD16 expression levels on peripheral NK cells of at least 60,000 (ABCs).
- In embodiments, the predetermined cut off of said biomarker is:
-
- a. a baseline peripheral NK cell count of at least 70 cells/μl, and
- b. baseline CD16 expression levels on peripheral NK cells of at least 60,000 (ABCs).
- In embodiments, predetermined cut off level a baseline peripheral NK cell count of at least 70 cells/μl. In embodiments, the predetermined cut of said biomarker is baseline CD16 expression levels on peripheral NK cells of at least 60,000 (ABCs).
- In embodiments, the predetermined cut off of said biomarker is:
-
- a. a baseline peripheral NK cell count of at least 80 cells/μl, or
- b. baseline CD16 expression levels on peripheral NK cells of at least 60,000 (ABCs).
- In embodiments, the predetermined cut off of said biomarker is:
-
- a. a baseline peripheral NK cell count of at least 80 cells/μl, and
- b. baseline CD16 expression levels on peripheral NK cells of at least 60,000 (ABCs).
- In embodiments, predetermined cut off level a baseline peripheral NK cell count of at least 80 cells/μl. In embodiments, the predetermined cut of said biomarker is baseline CD16 expression levels on peripheral NK cells of at least 60,000 (ABCs).
- In embodiments, the predetermined cut off of said biomarker is:
-
- a. a baseline peripheral NK cell count of at least 90 cells/μl, or
- b. baseline CD16 expression levels on peripheral NK cells of at least 60,000 (ABCs).
- In embodiments, the predetermined cut off of said biomarker is:
-
- a. a baseline peripheral NK cell count of at least 90 cells/μl, and
- b. baseline CD16 expression levels on peripheral NK cells of at least 60,000 (ABCs).
- In embodiments, predetermined cut off level a baseline peripheral NK cell count of at least 90 cells/μl. In embodiments, the predetermined cut of said biomarker is baseline CD16 expression levels on peripheral NK cells of at least 60,000 (ABCs).
- In embodiments, the predetermined cut off of said biomarker is:
-
- a. a baseline peripheral NK cell count of at least 100 cells/μl, or
- b. baseline CD16 expression levels on peripheral NK cells of at least 60,000 (ABCs).
- In embodiments, the predetermined cut off of said biomarker is:
-
- a. a baseline peripheral NK cell count of at least 100 cells/μl, and
- b. baseline CD16 expression levels on peripheral NK cells of at least 60,000 (ABCs).
- In embodiments, predetermined cut off level a baseline peripheral NK cell count of at least 100 cells/μl. In embodiments, the predetermined cut of said biomarker is baseline CD16 expression levels on peripheral NK cells of at least 60,000 (ABCs).
- An aspect is a method of identifying a subject having chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) or small lymphocytic lymphoma (SLL) that is responsive to treatment with an anti-CD19 antibody, said method comprising:
-
- a. providing a blood sample obtained from said subject prior to treatment with said anti-CD19 antibody,
- b. determining the level of at least one biomarker in said sample selected from the group consisting of:
- i. peripheral NK cell count, and
- ii. CD16 expression levels on peripheral NK cells,
- c. comparing the level of said at least one biomarker in said sample to a predetermined cut off level,
- wherein the baseline peripheral NK cell count is at least 50 cells/μl, at least 60 cells/μl, at least 70 cells/μl, at least 80 cells/μl, at least 90 cells/μl or at least 100 cells/μl and the baseline CD16 expression levels on peripheral NK cells is at least 60,000 (ABCs), and wherein the anti-CD19 antibody comprises an HCDR1 region comprising the sequence SYVMH (SEQ ID NO: 1), an HCDR2 region comprising the sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region comprising the sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region comprising the sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region comprising the sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region comprising the sequence MQHLEYPIT (SEQ ID NO: 6).
- An aspect is a method of identifying a subject having chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) or small lymphocytic lymphoma (SLL) that is responsive to treatment with an anti-CD19 antibody, said method comprising:
-
- a. providing a blood sample obtained from said subject prior to treatment with said anti-CD19 antibody,
- b. determining the level of at least one biomarker in said sample selected from the group consisting of:
- i. peripheral NK cell count, and
- ii. CD16 expression levels on peripheral NK cells,
- c. comparing the level of said at least one biomarker in said sample to a predetermined cut off level,
- wherein the baseline peripheral NK cell count is at least 100 cells/μl, or the baseline CD16 expression levels on peripheral NK cells is at least 60,000 (ABCs), and wherein the anti-CD19 antibody comprises an HCDR1 region comprising the sequence SYVMH (SEQ ID NO: 1), an HCDR2 region comprising the sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region comprising the sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region comprising the sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region comprising the sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region comprising the sequence MQHLEYPIT (SEQ ID NO: 6).
- In embodiments, the predetermined cut of said biomarker is:
-
- a. baseline peripheral NK cell count of at least 100 cells/μl, and
- b. baseline CD16 expression levels on peripheral NK cells of at least 60,000 (ABCs).
- In embodiments, the predetermined cut off level of said biomarker is a baseline peripheral NK cell count of at least 50 cells/μl, at least 75 cells/μl, at least 100 cells/μl, at least 125 cells/μl, at least 150 cells/μl, at least 175 cells/μl, at least 200 cells/μl, at least 225 cells/μl, or at least 250 cells/μl. In embodiments, the predetermined cut off level of said biomarker is baseline CD16 expression levels on peripheral NK cells of at least 45,000 ABCs, at least 60,000 ABCs, at least 75,000 ABCs, or at least 90,000 ABCs.
- An aspect is a method of treating a patient having chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) or small lymphocytic lymphoma (SLL) with an anti-CD19 antibody, the method comprising
-
- a. obtaining a baseline peripheral NK cell count in the patient, or a baseline CD16 expression level on the peripheral NK cells of the patient, and
- b. administering an effective amount of the anti-CD19 antibody to the patient having a baseline peripheral NK cell count of at least 50 cells/μl, at least 60 cells/μl, at least 70 cells/μl, at least 80 cells/μl, at least 90 cells/μl or at least 100 cells/μl or a baseline CD16 expression level on the peripheral NK cells of at least 60,000 (ABCs).
- An aspect is a method of treating a patient having chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) or small lymphocytic lymphoma (SLL) with an anti-CD19 antibody, the method comprising
-
- a. obtaining a baseline peripheral NK cell count in the patient, or a baseline CD16 expression level on the peripheral NK cells of the patient, and
- b. administering an effective amount of the anti-CD19 antibody to the patient having a baseline peripheral NK cell count of at least 100 cells/μl or a baseline CD16 expression level on the peripheral NK cells of at least 60,000 (ABCs).
- In embodiments, the method of treating a patient chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) or small lymphocytic lymphoma (SLL) with an anti-CD19 antibody, comprises
-
- a. obtaining an baseline peripheral NK cell count in the patient, and
- b. administering an effective amount of the anti-CD19 antibody to the patient having an NK cell count of at least 50 cells/μl, at least 60 cells/μl, at least 70 cells/μl, at least 80 cells/μl, at least 90 cells/μl or at least 100 cells/μl.
- In embodiments, the method of treating a patient chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) or small lymphocytic lymphoma (SLL) with an anti-CD19 antibody, comprises
-
- a. obtaining an baseline peripheral NK cell count in the patient, and
- b. administering an effective amount of the anti-CD19 antibody to the patient having an NK cell count of at least 50 cells/μl, at least 60 cells/μl, at least 70 cells/μl, at least 80 cells/μl, at least 90 cells/μl or at least 100 cells/μl.
- In embodiments, the method of treating a patient chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) or small lymphocytic lymphoma (SLL) with an anti-CD19 antibody, comprises
-
- a. obtaining an baseline peripheral NK cell count in the patient, and
- b. administering an effective amount of the anti-CD19 antibody to the patient having an NK cell count of at least 100 cells/μl.
- In embodiments, the method of treating a patient having chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) or small lymphocytic lymphoma (SLL) with an anti-CD19 antibody, comprises
-
- a. obtaining baseline CD16 expression levels on the peripheral NK cells of the patient, and
- b. administering an effective amount of the anti-CD19 antibody to the patient having CD16 levels on the NK cells of at least 60,000 (ABCs).
- In embodiments, the anti-CD19 antibody is administered to patients having both a baseline peripheral NK cell count of of at least 50 cells/μl, at least 60 cells/μl, at least 70 cells/μl, at least 80 cells/μl, at least 90 cells/μl or at least 100 cells/μl, and a baseline CD16 expression level on peripheral NK cells of at least 60,000 (ABCs).
- In embodiments, the anti-CD19 antibody is administered to patients having both a baseline peripheral NK cell count of at least 100 cells/μl, and a baseline CD16 expression level on peripheral NK cells of at least 60,000 (ABCs).
- In embodiments, the anti-CD19 antibody is administered to patients having a baseline peripheral NK cell count of at least 50 cells/μl, at least 75 cells/μl, at least 100 cells/μl, at least 125 cells/μl, at least 150 cells/μl, at least 175 cells/μl, at least 200 cells/μl, at least 225 cells/μl, or at least 250 cells/μl. In embodiments, the anti-CD19 antibody is administered to patients having baseline CD16 expression levels on peripheral NK cells of at least 45,000 ABCs, at least 60,000 ABCs, at least 75,000 ABCs, or at least 90,000 ABCs.
- An aspect is a method of treating a patient having chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) or small lymphocytic lymphoma (SLL) with an anti-CD19 antibody, said method comprising:
-
- a. providing a sample obtained from said subject prior to treatment with said anti-CD19 antibody,
- b. determining the level of at least one biomarker in said sample selected from the group consisting of:
- i. peripheral NK cell count, and
- ii. CD16 expression levels on peripheral NK cells,
- c. comparing the level of said at least one biomarker in said sample to a predetermined cut off level,
- d. administering an effective amount of anti-CD19 antibody to the patient having an peripheral NK cell count of at least 100 cells/μl or CD16 expression level on the peripheral NK cells of at least 60,000 (ABCs).
- An aspect is a method of treating a patient having chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) or small lymphocytic lymphoma (SLL) comprising administering an effective amount of an anti-CD19 antibody to the patient if
-
- a. the baseline peripheral NK cell count of the patient is at least 100 cells/μl or
- b. the baseline CD16 expression levels on peripheral NK cells is at least 60,000 (ABCs).
- An aspect is a method of treating a patient having chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) or small lymphocytic lymphoma (SLL) comprising
-
- a. obtaining the peripheral NK cell count of the patient,
- b. administering an effective amount of an anti-CD19 antibody to patients having peripheral NK cell counts of at least 100 cells/μl.
- An aspect is a method of treating a patient having chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) or small lymphocytic lymphoma (SLL) comprising
-
- a. obtaining the CD16 expression levels on the peripheral NK cells of the patient,
- b. administering an effective amount of an anti-CD19 antibody to patients having an CD16 expression levels on the peripheral NK cells of at least 60,000 (ABCs).
- In embodiments, anti-CD19 antibody is administered to patients having both a baseline peripheral NK cell count of at least 100 cells/μl and a baseline CD16 expression level on peripheral NK cells of at least 60,000 (ABCs). In embodiments, the anti-CD19 antibody is administered to patients having a baseline peripheral NK cell count of at least 50 cells/μl, at least 75 cells/μl, at least 100 cells/μl, at least 125 cells/μl, at least 150 cells/μl, at least 175 cells/μl, at least 200 cells/μl at least 225 cells/μl, or at least 250 cells/μl. In embodiments, the anti-CD19 antibody is administered to patients having baseline CD16 expression levels on peripheral NK cells of at least 45,000 ABCs, at least 60,000 ABCs, at least 75,000 ABCs, or at least 90,000 ABCs.
- In embodiments the baseline peripheral NK cell count or baseline CD16 levels (ABCs) on the peripheral NK cells is obtained from a blood sample taken from the patient. In embodiments the peripheral NK cell count and/or the CD16 expression levels are measured prior to administration of the anti-CD19 antibody.
- In embodiments, the antibody specific for CD19 comprises an HCDR1 region comprising the sequence SYVMH (SEQ ID NO: 1), an HCDR2 region comprising the sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region comprising the sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region comprising the sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region comprising the sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region comprising the sequence MQHLEYPIT (SEQ ID NO: 6).
- In embodiments the baseline peripheral NK cell count or baseline CD16 expression levels on the peripheral NK cells is obtained from a blood sample taken from the patient.
- In an embodiment, the patient has non-Hodgkin's lymphoma. In embodiments, the non-Hodgkin's lymphoma is selected from the group consisting of follicular lymphoma, small lymphocytic lymphoma, mucosa-associated lymphoid tissue, marginal zone, diffuse large B cell, Burkitt's, and mantle cell. In an embodiment, the non-Hodgkin's lymphoma is follicular lymphoma. In an embodiment, the non-Hodgkin's lymphoma is indolent non-Hodgkin's lymphoma. In an embodiment, the non-Hodgkin's lymphoma is small lymphocytic lymphoma. In an embodiment, the non-Hodgkin's lymphoma is mucosa-associated lymphoid tissue. In an embodiment, the non-Hodgkin's lymphoma is marginal zone lymphoma. In an embodiment, the non-Hodgkin's lymphoma is diffuse large B cell lymphoma. In an embodiment, the non-Hodgkin's lymphoma is Burkitt's lymphoma. In an embodiment, the non-Hodgkin's lymphoma is mantle cell lymphoma. In an embodiment, the patient has chronic lymphocytic leukemia. In an embodiment, the patient has acute lymphoblastic leukemia. In an embodiment, the patient has small lymphocytic lymphoma (SLL).
- In embodiments, the treatment results in the therapeutic effect selected from the group consisting of Disease Control Rate (DCR) and longer duration of Progression Free Survival.
- In embodiments, the treatment further comprises administration of an effective amount of a nitrogen mustard. In an embodiment that nitrogen mustard is bendamustine. In embodiments, the treatment further comprises administration of an effective amount of a purine analog. In embodiments, the purine analog is fludarabine. In embodiments, the treatment further comprises administration of an effective amount of a Bruton's tyrosine kinase (BTK) inhibitor. In embodiments, the Bruton's tyrosine kinase (BTK) inhibitor is ibrutinib. In embodiments, the treatment further comprises administration of an effective amount of a phosphoinositide 3-kinase inhibitor. In an embodiment the phosphoinositide 3-kinase inhibitor is idelalisib. In embodiments, the treatment further comprises administration of an effective amount of a thalidomide analog. In an embodiment, the thalidomide analog is lenalidomide. In embodiments, the treatment further comprises administration of an effective amount of a BCL-2 inhibitor. In an embodiment, the BCL-2 inhibitor is venetoclax.
- As the exemplified anti-CD19 antibody and other anti-CD19 antibodies bind CD19, it is believed that similar results may be seen with other anti-CD19 antibodies. Other anti-CD19 antibodies are described in U.S. patent application Ser. No. 12/377,251 (Xencor), WO2005012493, WO2010053716 (Immunomedics); WO2007002223 (Medarex); WO2008022152 (Xencor); WO2008031056 (Medimmune); WO 2007/076950 (Merck Patent GmbH); WO 2009/052431 (Seattle Genetics); and WO2010095031 (Glenmark Pharmaceuticals), all of which are incorporated by reference in their entireties.
- In embodiments, the antibody specific for CD19 comprises an antibody that cross-competes with the antibody comprising an HCDR1 region comprising the sequence SYVMH (SEQ ID NO: 1), an HCDR2 region comprising the sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region comprising the sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region comprising the sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region comprising the sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region comprising the sequence MQHLEYPIT (SEQ ID NO: 6).
- In embodiments, the antibody specific for CD19 comprises an antibody that binds to the same epitope as an antibody comprising an HCDR1 region comprising the sequence SYVMH (SEQ ID NO: 1), an HCDR2 region comprising the sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region comprising the sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region comprising the sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region comprising the sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region comprising the sequence MQHLEYPIT (SEQ ID NO: 6).
- In embodiments, the antibody specific for CD19 comprises an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6).
- In embodiments, the antibody specific for CD19 comprises a variable heavy chain of the sequence
-
(SEQ ID NO: 10) EVOLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGY INPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGT YYYGTRVFDYWGQGTLVTVSS and a variable light chain of the sequence (SEQ ID NO: 11) DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQ LLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYP ITFGAGTKLEIK. - In an embodiment said antibody comprises a heavy chain constant domain of the sequence
-
(SEQ ID NO: 12) ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP KSCDKTHTCPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVS HEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGK EYKCKVSNKALPAPEEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK. - In an embodiment, the antibody specific for CD19 comprises a light chain constant domain of the sequence RTVAAPSVFI FP PS DEQLKSGTASVVCLLN N FYPREAKVQWKVDNALQSG NSQESVTEQDS KD STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC. (SEQ ID NO: 13).
- In an embodiment, the antibody specific for CD19 comprises a heavy chain having the sequence
-
(SEQ ID NO: 8) EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGY INPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGT YYYGTRVFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ TYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPDVFLFPPK PKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQF NSTFRVVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKTISKTKGQPREP QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP MLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG K - In an embodiment, the antibody specific for CD19 comprises a light chain having the sequence
-
(SEQ ID NO: 9) DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQ LLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYP ITFGAGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK VQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE VTHQGLSSPVTKSFNRGEC - Embodiments comprise a pharmaceutical composition. In embodiments, the composition comprises an acceptable carrier. In embodiments, the composition is administered in an effective amount.
- The scope of the MOR00208C201 clinical study included the assessment of several exploratory biomarkers. As part of this initiative baseline peripheral T and NK cell counting was performed at the clinical sites.
- T cells are a type of lymphocyte (a subtype of white blood cell) that play a central role in cell-mediated immunity. They can be distinguished from other lymphocytes, such as B cells and NK cells, by the presence of a T-cell receptor on the cell surface.
- Natural killer cells or NK cells are a type of cytotoxic lymphocyte critical to the innate immune system. NK cells provide rapid responses to viral-infected cells, acting at around 3 days after infection, and respond to tumor formation. Typically, immune cells detect major histocompatibility complex (MHC) presented on infected cell surfaces, triggering cytokine release, causing lysis or apoptosis. NK cells are unique, however, as they have the ability to recognize stressed cells in the absence of antibodies and MHC, allowing for a much faster immune reaction.
- TriTest CD3 FITC/CD16+CD56 PE/CD45 PerCP (with TruCOUNT tubes), BD Biosciences, Cat: 340403 (US); 342442 (Europe). Pipettors and pipet tips capable of delivering 20 μL, 50 μL and 450 μL, Gilson Inc. FACS Lysing Solutions, BD Biosciences, Cat: 349202.
- Whole blood is stained with fluorochrome-labeled antibodies (TriTEST reagents) that bind specifically to leucocyte surface antigens. The cells travel past the laser beam and scatter the laser light. The stained cells fluoresce. These scatter and fluorescence signals, detected by the instrument, provide information about the cell's size, internal complexity, and relative fluorescence intensity. TriTEST reagents employ fluorescence triggering, allowing direct fluorescence gating of the NK- and T-cell lymphocyte population to reduce contamination of unlysed or nucleated red blood cells in the gate.
- For each patient sample, a TruCOUNT Tube was labelled with the sample identification number. 20 μL of TriTEST CD3/CD16+CD56/CD45 reagent was pipetted into the bottom of the tube. 50 μL of well-mixed, anticoagulated whole blood was pipetted into the bottom of the tube. Anticoagulated blood (EDTA) stored at room temperature (20-25° C.) must be stained within 24 hours of draw and analyzed within 6 hours of staining (keep at room temperature and protected from light). The tube was vortexed gently to mix. The tube was incubated for 15 minutes in the dark at room temperature (20-25° C.). 450
μL 1× FACS Lysing Solution was added to the tube. The tube was vortexed and incubated again for 15 minutes in the dark at room temperature (20-25° C.). - Using TruCOUNT Tubes, a known volume of sample is stained directly in a TruCOUNT Tube. The lyophilized pellet in the tube dissolves, releasing a known number of fluorescent beads. During analysis, the absolute number (cells/μL) of positive cells in the sample can be determined by comparing cellular events to bead events.
- The cells were vortexed thoroughly (at low speed) to reduce aggregation before running them on the flow cytometer.
- The CD45 vs SSC dot plot was visually inspected. Lymphocytes appear as a bright, compact cell population with low to moderate SSC. Monocytes (M) and granulocytes (G) appear as distinct populations. Analysis was completed when the cell populations of monocytes and lymphocytes showed clear separation.
- Lymphocytes were first gated as CD45 positive, low SSC cell population. CD16/CD56 vs CD3 were pre-selected. T-cells (T) should appear as a compact bright CD3 positive cluster. NK-cells (NK) should appear as a compact bright CD16/CD56 positive cluster. Gating was completed and the T, and NK cells were counted.
- Bead event counts were done using a CD16/CD56 vs CD3 plot without any pre-selected gate. Beads should appear as a PE/FITC double positive cluster.
- The absolute number (cells/μL blood) of T cells or NK cells in the sample was determined by comparing cellular events to bead events. Either MultiSET software or manual (using CellQuest or other software) data analysis was done. For manual counting, the number (#) of positive cellular acquired events was divided by the number (#) of acquired bead events, then multiplied by the (total TruCOUNT bead count (lot dependent) divided by whole blood sample volume of 50 μL). The result is absolute cell numbers per microliter.
-
-
- As part of MOR00208C201 clinical study, CD16 (an exploratory biomarker) was quanitified on peripheral NK Cells centrally by ICON Central Laboratories (Farmingdale, N.Y.).
- Antibodies: CD45 AmCyan (Clone 2D1, BD Biosciences, Cat #339192); CD3 FITC (Clone UCHT1, BioLegend, Cat #300406); Mouse IgG FITC (Clone MOPC-21, BioLegend, Cat #400110); CD16 PE (Clone 3G8, BioLegend, Cat #302008); MOR00208; Mouse IgG PE (Clone MOPC-21, BioLegend, Cat #400114); CD56 PerCP-Cy5.5 (Clone HCD56, BioLegend, Cat #318322); and Mouse IgG PerCP-Cy5.5 (Clone MOPC-21, BioLegend, Cat #400150).
- Material: PharmaTherm insulated shippers (Intelsius, Catalog #PHT014); BD Vacutainer® CPT™ Mononuclear Cell Preparation Tube—Sodium Heparin (16×125 mm/8 mL) (BD, Catalog #362753); BD Falcon ™12×75 mm round-bottom tubes (BD, Catalog #352052); CS&T Beads (BD Biosciences Cat #642212); Fetal Bovine Serum (FBS), heat inactivated (Sigma F4135, or equivalent); Dulbecco's PBS without Ca++ and Mg++ (Gibco, Cat #14190, or equivalent); BD Falcon, Cell Strainer, 100 μm, yellow (BD Bioscience, Cat #352360); FACS Buffer, 3% of heat inactivated FBS in 1× DPBS; Deionized water, laboratory stock; Crushed (wet) ice; Ice bucket; Aluminum foil; Conical Tubes, 50 mL; Conical Tubes, 15 mL; Sterile, filter pipette tips; BD Pharm Lyse Lysing Buffer (BD Biosciences, Cat #555899); ViViD LIVE/DEAD® Fixable Violet Dead Cell Stain Kit, for 405 nm excitation (Life Technologies, Cat #L34955); ArC Amine Reactive Beads (Life Technologies, Cat #A10346); BD QuantiBRITE Beads (BD Biosciences, Cat #340495); and 52 μm nylon mesh (Miami Aqua Culture, for Cat: Nylon 52 μm, 32% open area woven into material).
- Equipment: Centrifuge (refrigerated capability); Lab quake (Tube rocker); Vortex mixer; Laminar flow hood; Incubator (Set at 37° C., 5% CO2); Advia (cell counter); BD FACSCANTO II flow cytometer; Desi-Vac™ Container, 1.5 liters (VWR, Cat #62344-930); Humidity Sponge™ Indicating (VWR, Cat #61161-319); and Traceable Humidity-On-A-Card (VWR, Cat #15551-012).
-
TABLE 1 CD16 Quantification Assay Panel for PBMC (Peripheral Blood Mononuclear Cell) Tube PerCP- Description # V450 AmCyan FITC PE Cy5.5 APC Control 1 ViViD CD45 Ms IgG Ms IgG Ms IgG — Tube I CD16 2 ViViD CD45 CD3 CD16 CD56 — ABC - Patient's peripheral blood was collected in a CPT tubes and shipped overnight from clinical sites to the central lab in insulated shippers. CPT tubes were centrifuged for 25 min at 1800×g at RT with brake ON. After centrifugation, CPT tubes were immediately inverted and placed for 10 min on the lab quake to resuspend PBMC layer in autologous plasma and resolve majority of formed cell aggregates. Under sterile conditions, homogenized PBMC/plasma suspension was decanted slowly into the center of 100 μm cell strainer resting on top of a sterile 50 mL conical tube. An equal volume of 1× DPBS was added to the PBMC/plasma suspension (approximately 4 mL) in 15 mL conical tube. The tubes were centrifuged at 300×g for 10 min at 4° C. and supernatant removed. The t ubes were vortexed to resuspend cell pellet. The cell pellet was washed with DBPS, centrifuged, supernatant removed and resuspended by vortexing. The washed PBMC suspension was added into an eppendorf tube containing 1 μL ViViD stock solution; incubated for 15 min on ice and kept in dark (cover with aluminum foil). The stained ViViD PBMC were transferred into a new labeled conical tube and then ice cold FACS Buffer was added. The cells were centrifuged and vortexed again for resuspension. Polystyrene falcon tubes were labeled for each sample (Table 1). The antibodies or isotype control antibodies were added to the appropriate tubes. The aliquot of ViViD stained PBMCs was added to each tube (Table 1). The tubes were vortexed and incubate. FACS Buffer was added and the cells were centrifuged and vortexed again for resuspension. BD Pharm Lyse Lysing Buffer was added, and the cells were vortexed, centrifuge and aspirated to remove supernatant and vortexed again to resuspend. FACS Buffer was added again and the cells were centrifuged and vortexed again for resuspension. Samples were then acquired on the FACSCanto II Cytometer and ABCs (Antibodies Bound Per Cell) were estimated from standardized MFI as described in lyer S, et al., Expression of CD69 on activated T cells using R-phycoerythrin labeled beads, Cytometry, 1996; #AC78 (Suppl.8):113 and Iyer S., et al., QuantiBRITE: A New Standard for Fluorescence Quantitation, Becton Dickinson Immunocytometry Systems, San Jose, Calif. 1997. White Paper.
- The study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL) ClinicalTrials.gov Identifier: NCT01685008 is no longer recruiting.
- The Inclusion Criteria were as follows:
- 1. Male or female patients ≥18 years of age.
- 2. Histologically-confirmed diagnosis according to REAL/WHO classification, of the following B-cell lymphomas: a.FL, b.MCL, c.DLBCL, d.Other indolent NHL (eg, MZL/MALT).
- 3. Patients' NHL must have progressed after at least 1 prior rituximab containing regimen.
- 4. One site of measurable disease by magnetic resonance imaging (MRI) or computed tomography (CT) scan defined as at least one lesion that measures at least 1.5×1.5 cm, with the exception: For patients with MCL only, patients with nonmeasurable disease but evaluable sites (bone marrow, spleen, peripheral blood, gastrointestinal tract) can be enrolled.
- 5. Patients who have previously received an autologous stem cell transplantation must be at least 4 weeks post-transplant before study drug administration and must have exhibited a full haematological recovery.
- 6. Discontinued previous monoclonal antibody therapy (except rituximab) or radioimmunotherapy administration for at least 60 days before study drug administration.
- 7. Off rituximab for at least 14 days before the screening visit and be confirmed to have either no response or have disease progression after rituximab treatment.
- 8. Patients with DLBCL had a positive [18F]fluorodeoxyglucose-positron emission tomography (FDG-PET) scan at baseline (Cheson response criteria).
- 9. Life expectancy of >3 months.
- 10. ECOG performance status of <3.
- 11. Laboratory criteria at screening: a) Absolute neutrophil count (ANC)≥1.0 (1000/mm3) b) Platelet count≥75×109/L without previous transfusion within 10 days of first study drug administration. c) Haemoglobin≥8.0 g/dL (may have been transfused). d) Serum creatinine<2.0×upper limit of normal (ULN). e) Total bilirubin≤2.0×ULN. f) Alanine transaminase (ALT) and aspartate aminotransferase (AST)≤2.5×ULN.
- 12. If a female of childbearing potential, a negative pregnancy test must be confirmed before enrolment and use of double-barrier contraception, oral contraceptive plus barrier contraceptive, or confirmation of having undergone clinically documented total hysterectomy and/or oophorectomy, tubal ligation.
- 13. If a male, an effective barrier method of contraception must be used during the study and for 3 months after the last dose if the patient is sexually active with a female of childbearing potential.
- 14. Able to comply with all study-related procedures, medication use, and evaluations.
- 15. Able understand and give written informed consent and comply with the study protocol.
- The exclusion Criteria were as follows:
- 1. Previous treatment with cytotoxic chemotherapy, immunotherapy, radiotherapy or other lymphoma specific therapy within 14 days before the screening visit or patient has not recovered from side effects of previous lymphoma-specific therapy.
- 2. Treatment with a systemic investigational agent within 28 days before the screening visit.
- 3. Previous treatment with an anti-CD19 antibody or fragments.
- 4. Previous allogenic stem cell transplantation.
- 5. Known or suspected hypersensitivity to the excipients contained in the study drug formulation.
- 6. Clinically significant cardiovascular disease or cardiac insufficiency,cardiomyopathy, preexisting clinically significant arrhythmia, acute myocardial infarction within 3 months of enrolment, angina pectoris within 3 months of enrolment.
- 7. Clinical or laboratory evidence of active hepatitis B or hepatitis C.
- 8. History of HIV infection.
- 9. Any active systemic infection (viral, fungal, or bacterial) requiring active parenteral antibiotic therapy within 4 weeks of study drug administration.
- 10. Current treatment with immunosuppressive agents other than prescribed corticosteroids (not more than 10-mg prednisone equivalent).
- 11. Major surgery or radiation therapy within 4 weeks before first study drug administration.
- 12. Systemic diseases (cardiovascular, renal, hepatic, etc) that would prevent study treatment in the investigator's opinion.
- 13. History or clinical evidence of central nervous system (CNS), meningeal, or epidural disease, including brain metastasis.
- 14. Active treatment/chemotherapy for another primary malignancy within the past 5 years.
- 15. Pregnancy or breastfeeding in women and women of childbearing potential not using an acceptable method of birth control.
- 16. History of noncompliance to medical regimens or patients who are considered potentially unreliable not cooperative.
- Patients were treated with MOR00208 as follows. Patients were treated with two 28 day cycles, where MOR00208 was given at a dose of 12 mg/kg on
days - As of the end of the study, the patient characteristics were as follows:
-
TABLE 2 Baseline characteristics DLBCL iNHL MCL Total Characteristic n = 35 n = 45 n = 12 n = 92 Age, years Median 71 66 64.5 66.5 Sex Male 24 (69) 21 (47) 11 (92) 56 (61) ECOG PS 0 20 (57) 33 (73) 7 (58) 60 (65) 1 12 (34) 11 (24) 4 (33) 27 (29) 2 3 (9) 1 (2) 1 (8) 5 (5) Rituximab refractory Yes 24 (69) 22 (49) 6 (50) 52 (57) No 11 (31) 23 (51) 6 (50) 40 (43) Last rituximab dose <6 mos 14 (40) 6 (13) 1 (8) 21 (23) Prior stem cell transplant Yes 2 (6) 7 (16) 1 (8) 10 (11) DoR to last prior therapy >12 months 3 (9) 18 (40) 4 (33) 25 (27) ≤12 months 26 (74) 25 (56) 7 (58) 58 (63) Unknown 6 (17) 2 (4) 1 (8) 9 (10) Baseline NK cell count >100 cells/μl 19 (54) 23 (51) 8 (67) 51 (55) ≤100 cells/μl 11 (31) 8 (18) 1 (8) 20 (22) Unknown 5 (14) 14 (31) 3 (25) 21 (23) Baseline CD16 expression >60000 ABCs 15 (43) 33 (73) 5 (42) 53 (58) on NK cells ≤60000 ABCs 11 (31) 5 (11) 4 (33) 20 (22) Unknown 9 (26) 7 (16) 3 (25) 19 (21) Baseline T cell count >500 cells/μl 20 (57) 26 (58) 8 (67) 54 (59) ≤500 cells/μl 10 (29) 6 (13) 1 (8) 17 (18) Unknown 5 (14) 13 (29) 3 (25) 21 (23) FcyRIIIa High affinity 5 (14) 4 (9) 1 (8) 10 (11) Low affinity 27 (77) 28 (62) 9 (57) 64 (70) Unknown 3 (9) 13 (29) 2 (17) 18 (20) FcyRIIa High affinity 11 (31) 10 (22) 3 (25) 24 (26) Low affinity 21 (60) 22 (49) 7 (58) 50 (54) Unknown 3 (9) 13 (29) 2 (17) 18 (18) DLBCL, diffuse large B-cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance status; iNHL, indolent non-Hodgkin's lymphoma (includes follicular lymphoma and other iNHL); MCL, mantle cell lymphoma; mos, months. (%) - Other iNHL means a heterogeneous group of not further specified indolent, not aggressive, NHL types, e.g. Marginal Cell Lymphoma, Marginal Zone Lymphoma, and Mucosa associated lymphoid tissue (MALT) lymphoma.
- The Key primary and secondary endpoints were as follows:
- Primary: Overall Response Rate (ORR)=CR+PR
- Secondary:
-
- Disease Control Rate (DCR)=CR+PR+SD
- Progression-free survival (PFS)
-
TABLE 3 Response DLBCL iNHL† MCL Total Best overall response,* n (%) n = 35 n = 45 n = 12 n = 92 Complete response, CR 2 (6) 5 (11) 0 7 (8) Partial response, PR 7 (20) 8 (18) 0 15 (16) Stable disease, SD 5 (14) 20 (44) 6 (50) 31 (34) Progressive disease 11 (31) 7 (16) 5 (42) 23 (25) Not evaluable‡ 10 (29) 5 (11) 1 (8) 16 (17) DCR (CR + PR + SD) 14 (40) 33 (73) 6 (50) 53 (58) ORR (CR + PR/all patients) 9 (26) 13 (29) 0 22 (24) ORR (CR + PR/evaluable 9 (36) 13 (33) 0 22 (29) patients§) Data are n (%). *Investigator assessed. †Includes follicular lymphoma and other indolent NHLs. ‡Post-baseline response assessment not performed/data unavailable. §n = 25, 40, 11 and 76, respectively. DCR, disease control rate; DLBCL, diffuse large B-cell lymphoma; iNHL, indolent non-Hodgkin's lymphoma; MCL, mantel cell lymphoma' ORR, overall response rate. - The response criteria in this study are those as defined in Table 4. All of them are based on the International Working Group Response Criteria (2007).
-
TABLE 4 Response Criteria Response Definition Nodal masses Spleen, liver Bone marrow CR Disappearance of a) FDG-avid or Not palpable, Infiltrate all evidence of PET positive prior nodules cleared on disease to therapy; mass of disappeared repeat biopsy; any size permitted if if indeterminate PET negative by morphology, b) Variable FDG- immunohistochemistry avid or PET should be negative; negative regression to normal size on CT PR Regression of ≥50% decrease in ≥50% decrease Irrelevant if measurable SPD of up to 6 largest in SPD of positive prior to disease and no dominant masses; no nodules (for therapy; cell new sites increase in size on single nodule in type should be CT greatest specified a) FDG-avid or transverse PET positive prior diameter); no to therapy; one or increase in size more PET positive of liver or at previously spleen involved site b) Variable FDG- avid or PET negative; regression on CT SD Failure to attain a) FDG-avid or CR/PR or PD PET positive prior to therapy; PET positive at prior sites of disease and no new sites on CT or PET b) Variable FDG- avid or PET negative; no change in size of previous lesions on CT Relapsed Any new lesion or Appearance of a new >50% increase New or disease or increase by ≥50% lesion(s) >1.5 cm in from nadir in the recurrent PD of previously any axis, ≥50% SPD of any involvement involved sites increase in SPD of previous from nadir more than one lesions node, or ≥50% increase in longest diameter of a previously identified node >1 cm in short axis Lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy Abbreviations: CR, complete remission; FDG, [18F]fluorodeoxyglucose; PET, positron emission tomography; CT, computed tomography; PR, partial remission; SPD, sum of the product of the diameters; SD, stable disease; PD, progressive disease - DCR (CR+PR+SD) was considered the most relevant efficacy endpoint the analysis of patient characteristic and biomarkers in this trial as the majority of patients with SD had marked target lesion reduction but as per study design were not treated beyond
cycle 3. Accordingly, patients having SD included in the analysis. - At least the following characteristics of patients were evaluated to determine if there existed a correlation between the characteristic and the observed DCR of patients treated with the anti-CD19 antibody: a) age, b) gender, c) if patients had received a dose of Rituximab within the last 6 months, d) whether the patients were Rituximab refractory, e) whether patients have the FCgammaRIIIa high or low affinity allele, f) whether patients have the FCgammaRIIa high or low affinity allele, g) whether patients had a duration of response to the previous treatment of greater than 12 months, h) baseline peripheral T cell counts (cells/μl), i) baseline peripheral NK cell count (cells/μl) and j) baseline CD16 expression on peripheral NK cells (Antibodies Bound per Cells—ABCs).
- Example 1 and Example 2 above were used to evaluate the baseline peripheral NK cell counts, T cell counts and baseline CD16 expression on peripheral NK cells. The data is shown in Table 2.
- A Receiver Operating Characteristic (ROC) analysis was used to analyse the predictivity, specifity and sensitivity and to determine the cut offs for the potential biomarkers of NK cell count, T cell count and CD16 expression (ABCs) on peripheral NK cells. A ROC plot displays the performance of a binary classification method with continuous or discrete ordinal output. It shows the sensitivity (the proportion of correctly classified positive observations) and specificity (the proportion of correctly classified negative observations) as the output threshold is moved over the range of all possible values. See Swets J A: The Relative Operating Characteristic in Psychology. Science 1973, 182: 990-1000, and Pepe MS: The statistical evaluation of medical tests for classification and prediction. Oxford: Oxford University Press; 2003. In the ROC context, the area under the curve (AUC) measures the performance of a classifier and is frequently applied for method comparison. A higher AUC means a better classification. The AUC for peripheral NK/T cell counts and for CD16 expression on NK cells is 0.66, 0.53 and 0.61 respectively (
FIGS. 3, 4 and 5 ). - In general the determination of the cut off depends on the objective the respective method is directed to. Various criteria such as maximum accuracy, maximum diagnostic odds ratio, minimal error rate, maximum sensitivity and/or maximum specificity would lead to a different determination of the cut off. In addition a balance between more of such criteria, e.g. sensitivity and specificity would also lead to a specific determination of the cut off.
- Therefore several methods or criteria for selecting optimal cutoffs exist, including methods maximizing accuracy, sensitivity+specificity, predictive values, diagnostic likelihood ratios or prevalence. Due to the asymetry of the CD16 expression-ROC curve (See
FIG. 4 ) the majority of methods result in a cut off of 60,000 ABC (the points with the greatest distance between ROC curve and the bisecting line) whereas, the symmetry of the NK cell count ROC curve (SeeFIG. 3 ) explains why different values for the best cut off could be obtained when applying different methods. In this particular study, for both biomarkers more weight was assigned to sensitivity and, therefore, 100 NK cells/μl and a CD16 expression level of 60,000 ABCs, respectively, were chosen as cut offs to analyze the DCR and PFS within the subgroups. For peripheral T cell counts, the AUC is 0.53 and the ROC curve is close to the bisectrix at any value of specificity and sensitivity therefore even selecting a different cut off than 500 cell//μl had no impact on the negative results of the DCR and PFS subgroup analysis. - The determination of the cut off can be balanced either in favor of sensitivity or specificity. If even more weight is assigned to sensitivity for the identification of the optimal cut-off the method would be different and a lower cut-off for the NK cell count is contemplated. In such case a cut off of at least 50 NK cells/μl is determined. Alternatively, a cut off of at least 60 NK cells/μl, at least 70 NK cells/μl, at least 80 NK cells/μl, at least 90 NK cells/μl or at least 100 NK cells/μl is determined.
- For maximizing the specificity of the disclosed method the cut-off for the NK cell count is increased and is determined between at least 100 NK cells/μl up to at least 150 NK cells/μl. Therefore for maximizing the specificity a cut off of at least 100 NK cells/μl, at least 110 NK cells/μl, at least 120 NK cells/μl, at least 130 NK cells/μl, at least 140 NK cells/μl or at least 150 NK cells/μl is selected.
- The cut off values determined in this particular study (100 NK cells/μl and a CD16 expression level of 60,000 ABCs) were used for the following statistical analysis.
- Forest plots were used to analyze all patient characteristics and biomarkers in order to determine the correlation of the individual characteristic with DCR. The results are shown in
FIG. 7 . Based upon the Forest Plot analysis of the different patient characteristics and their correlation to DCR, in DLBCL and iNHL patients the following characteristics showed statistically significant differences: 1) baseline peripheral NK cell count of at least 100 cells/μl and baseline expression of CD16 on peripheral NK cells of at least 60,000 ABCs (x2 unadjusted p value=0.029/0.003) (FIG. 7 ). - In order to ensure that CD16 expression and NK cell count were independent characteristics, which did not influence on the other, a parametric and nonparametric correlation analysis was done. Data on CD16 expression and NK cell count was available for 51 patients. Pearson's r was 0,019 with a two-tailed p value=0.9 and Spearman's r was 0,036 with a two-tailed p value=0.8. The results are graphically presented in
FIG. 6 . In conclusion, CD16 expression and NK cell count at the determined thresholds are not correlated, therefore, they are considered fully independent predictors of the probability of a patient for benefiting from MOR00208 treatment. - The following characteristics were not found to be predictive of DCR: a) age, b) gender, c) if patients had received a dose of Rituximab within the last 6 months, d) whether the patients were Rituximab refractory, e) whether patients have the FCgammaRIIIa high or low affinity allele, f) whether patients have the FCgammaRIIa high or low affinity allele, g) whether patients had a duration of response to the treatment of greater than 12 months, or h) baseline peripheral T cell counts. See
FIG. 7 . - Both 1) baseline peripheral NK cell counts and 2) baseline CD16 expression on peripheral NK cells showed clear correlations to patient response with MOR00208 therapy. Specifically, patients having a baseline NK cell count of at least 100 cells/μl correlated with a higher Disease Control Rate (DCR). DCR includes patients have Complete Response (CR)+Partial Response (PR)+Stable Disease (SD). In addition, patients having a baseline CD16 expression on peripheral NK cells of at least 60,000 ABCs correlated with higher Disease Control Rate (DCR).
- Progression Free Survival (PFS) is the length of time during and after the treatment of a disease that a patient lives with the disease but it does not get worse. This is an additional important endpoint of a clinical trial, and an indicator of effectiveness in patients. PFS was compared within the following patient characteristics: a) baseline peripheral NK cell count of at least 100 cells/μl or less, b) baseline CD16 expression on peripheral NK cells of at least 60,000 ABCs or less, and c) baseline peripheral T cell count of at least 500 cells/μl or less. The results are shown in
FIGS. 8-10 . The PFS comparing patients having NK cell counts having at least 100 cells/μl as compared to patients having lower NK cell counts showed a statistically significant difference with a HR of 0.1561 (unadjusted log-rank p value=0.0003). This further confirms the predictivity of NK cells counts in the response of patients treated with MOR00208 of those patients having CLL, NHL, ALL or SLL. - It is to be understood that the description, specific examples and data, while indicating exemplary embodiments, are given by way of illustration and are not intended to limit the present invention. Various changes and modifications within the present invention will become apparent to the skilled artisan from the discussion, disclosure and data contained herein, and thus are considered part of the invention.
Claims (13)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16171885 | 2016-05-30 | ||
EP16171885.3 | 2016-05-30 | ||
PCT/EP2017/063045 WO2017207574A1 (en) | 2016-05-30 | 2017-05-30 | Methods for predicting therapeutic benefit of anti-cd19 therapy in patients |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2017/063045 A-371-Of-International WO2017207574A1 (en) | 2016-05-30 | 2017-05-30 | Methods for predicting therapeutic benefit of anti-cd19 therapy in patients |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/824,266 Continuation US20220283166A1 (en) | 2016-05-30 | 2022-05-25 | Methods for predicting therapeutic benefit of anti-cd19 therapy in patients |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190195879A1 true US20190195879A1 (en) | 2019-06-27 |
Family
ID=56116221
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/305,482 Abandoned US20190195879A1 (en) | 2016-05-30 | 2017-05-30 | Methods for predicting therapeutic benefit of anti-cd19 therapy in patients |
US17/824,266 Pending US20220283166A1 (en) | 2016-05-30 | 2022-05-25 | Methods for predicting therapeutic benefit of anti-cd19 therapy in patients |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/824,266 Pending US20220283166A1 (en) | 2016-05-30 | 2022-05-25 | Methods for predicting therapeutic benefit of anti-cd19 therapy in patients |
Country Status (26)
Country | Link |
---|---|
US (2) | US20190195879A1 (en) |
EP (2) | EP3465214B1 (en) |
JP (2) | JP7066639B2 (en) |
KR (1) | KR102416144B1 (en) |
CN (2) | CN115932265A (en) |
AU (1) | AU2017272608B2 (en) |
BR (1) | BR112018074603A2 (en) |
CA (1) | CA3025823A1 (en) |
CY (1) | CY1124768T1 (en) |
DK (1) | DK3465214T3 (en) |
EA (1) | EA201892542A1 (en) |
ES (1) | ES2878156T3 (en) |
HR (1) | HRP20210938T1 (en) |
HU (1) | HUE054860T2 (en) |
IL (1) | IL263103B2 (en) |
LT (1) | LT3465214T (en) |
MA (1) | MA45124B1 (en) |
MD (1) | MD3465214T2 (en) |
MX (2) | MX2018014702A (en) |
PL (1) | PL3465214T3 (en) |
PT (1) | PT3465214T (en) |
RS (1) | RS62155B1 (en) |
SG (2) | SG10201911958SA (en) |
SI (1) | SI3465214T1 (en) |
WO (1) | WO2017207574A1 (en) |
ZA (1) | ZA201808647B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220242952A1 (en) * | 2019-05-03 | 2022-08-04 | Morphosys Ag | Anti-cd19 therapy in patients having a limited number of nk cells |
EP4051315A1 (en) * | 2019-10-31 | 2022-09-07 | MorphoSys AG | Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma |
AU2020375149A1 (en) * | 2019-10-31 | 2022-05-12 | Incyte Corporation | Sequential anti-CD19 therapy |
WO2022117799A2 (en) * | 2020-12-04 | 2022-06-09 | Morphosys Ag | Anti-cd19 combination therapy |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100531798C (en) * | 1998-08-11 | 2009-08-26 | 拜奥根Idec公司 | Combination therapies for B-cell lynphomas comprising administration of anti-CD20 antibody |
DE60234585D1 (en) | 2001-02-27 | 2010-01-14 | Us Government | |
WO2005016326A2 (en) | 2003-07-11 | 2005-02-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
US7109304B2 (en) | 2003-07-31 | 2006-09-19 | Immunomedics, Inc. | Humanized anti-CD19 antibodies |
US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
CA2611814A1 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
PT1966245E (en) | 2005-12-30 | 2011-08-31 | Merck Patent Gmbh | Anti-cd19 antibodies with reduced immunogenicity |
EP2059536B1 (en) | 2006-08-14 | 2014-01-08 | Xencor, Inc. | Optimized antibodies that target cd19 |
PL2066349T3 (en) | 2006-09-08 | 2012-09-28 | Medimmune Llc | Humanized anti-cd19 antibodies and their use in treatment of tumors, transplantation and autoimmune diseases |
US20100167315A1 (en) * | 2006-09-13 | 2010-07-01 | Glycode | Method for investigating the response to a treatment with a monoclonal antibody |
WO2008150494A1 (en) | 2007-05-30 | 2008-12-11 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
PT2211904T (en) | 2007-10-19 | 2016-11-02 | Seattle Genetics Inc | Cd19 binding agents and uses thereof |
WO2010095031A2 (en) | 2009-02-23 | 2010-08-26 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to cd19 and their uses |
WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
CA2817842A1 (en) * | 2010-11-15 | 2012-05-24 | Medimmune, Llc | Combination therapy for b cell lymphomas |
EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
KR20200058583A (en) * | 2011-08-16 | 2020-05-27 | 모르포시스 아게 | Combination therapy with an anti-cd19 antibody and a nitrogen mustard |
EP2744826B1 (en) * | 2011-08-16 | 2022-02-09 | MorphoSys AG | Combination therapy with an anti-cd19 antibody and a purine analog |
CA2858906A1 (en) * | 2011-12-12 | 2013-06-20 | Pikamab, Inc | Predicting responsiveness to antibody maintenance therapy |
CN106029098A (en) * | 2014-02-25 | 2016-10-12 | 免疫医疗公司 | Humanized RFB4 anti-CD22 antibody |
WO2015195498A1 (en) | 2014-06-16 | 2015-12-23 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (cll) |
WO2016005548A1 (en) * | 2014-07-11 | 2016-01-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing hematological cancers |
-
2017
- 2017-05-30 HU HUE17728484A patent/HUE054860T2/en unknown
- 2017-05-30 IL IL263103A patent/IL263103B2/en unknown
- 2017-05-30 BR BR112018074603-7A patent/BR112018074603A2/en unknown
- 2017-05-30 MX MX2018014702A patent/MX2018014702A/en unknown
- 2017-05-30 EP EP17728484.1A patent/EP3465214B1/en active Active
- 2017-05-30 MD MDE20190405T patent/MD3465214T2/en unknown
- 2017-05-30 DK DK17728484.1T patent/DK3465214T3/en active
- 2017-05-30 SG SG10201911958SA patent/SG10201911958SA/en unknown
- 2017-05-30 LT LTEP17728484.1T patent/LT3465214T/en unknown
- 2017-05-30 MA MA45124A patent/MA45124B1/en unknown
- 2017-05-30 WO PCT/EP2017/063045 patent/WO2017207574A1/en unknown
- 2017-05-30 PL PL17728484T patent/PL3465214T3/en unknown
- 2017-05-30 SI SI201730823T patent/SI3465214T1/en unknown
- 2017-05-30 KR KR1020187038026A patent/KR102416144B1/en active IP Right Grant
- 2017-05-30 SG SG11201810159TA patent/SG11201810159TA/en unknown
- 2017-05-30 JP JP2018562324A patent/JP7066639B2/en active Active
- 2017-05-30 EP EP21170716.1A patent/EP3916392B1/en active Active
- 2017-05-30 PT PT177284841T patent/PT3465214T/en unknown
- 2017-05-30 RS RS20210893A patent/RS62155B1/en unknown
- 2017-05-30 EA EA201892542A patent/EA201892542A1/en unknown
- 2017-05-30 CA CA3025823A patent/CA3025823A1/en active Pending
- 2017-05-30 ES ES17728484T patent/ES2878156T3/en active Active
- 2017-05-30 CN CN202211271570.5A patent/CN115932265A/en active Pending
- 2017-05-30 US US16/305,482 patent/US20190195879A1/en not_active Abandoned
- 2017-05-30 CN CN201780033793.9A patent/CN109313194B/en active Active
- 2017-05-30 AU AU2017272608A patent/AU2017272608B2/en active Active
-
2018
- 2018-11-28 MX MX2021014963A patent/MX2021014963A/en unknown
- 2018-12-20 ZA ZA2018/08647A patent/ZA201808647B/en unknown
-
2021
- 2021-06-11 HR HRP20210938TT patent/HRP20210938T1/en unknown
- 2021-07-13 CY CY20211100629T patent/CY1124768T1/en unknown
-
2022
- 2022-04-27 JP JP2022072884A patent/JP2022119764A/en active Pending
- 2022-05-25 US US17/824,266 patent/US20220283166A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220283166A1 (en) | Methods for predicting therapeutic benefit of anti-cd19 therapy in patients | |
EP4045083B1 (en) | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia | |
IL295023A (en) | Antibodies and fusion proteins that bind to ccr8 and uses thereof | |
US20210147568A1 (en) | Anti-cd47 based treatment of blood cancer | |
JP2023179425A (en) | Obinutuzumab treatment of dlbcl patient subgroup | |
US20220242952A1 (en) | Anti-cd19 therapy in patients having a limited number of nk cells | |
NZ788788A (en) | Methods for predicting therapeutic benefit of anti-CD19 therapy in patients | |
EA040320B1 (en) | METHODS FOR PREDICTING THE THERAPEUTIC EFFECT OF THERAPY USING ANTIBODIES TO CD19 IN PATIENTS | |
TW202128741A (en) | Chimeric antigen receptor t cell therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MORPHOSYS AG., GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ENDELL, JAN;WINDERLICH, MARK;BOXHAMMER, RAINER;REEL/FRAME:047986/0882 Effective date: 20190114 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: INCYTE CORPORATION, DELAWARE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MORPHOSYS AG;MORPHOSYS US INC.;REEL/FRAME:066645/0172 Effective date: 20240205 |